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This volume  sets out  a  comparative  analysis of rules  and regulations 
in the EEC  countries for three different diseases  :  Foot- and-Mouth 
Disease,  Swine  Fever and Newcastle Disease in the three most  important 
species for  food  production (cattle, pigs  and poultry). 
The  following divisions also  assisted in the work  :  "Statistics, Balance-
sheets, General  Studies"  and  "Harmonization of laws,  regulations  and 
admini strati  ve  provisions relating to veterinary matters  and  zoot  echni  os  n. 
* 
*  * 
This  study does not necessarily reflect the views of the Commission  of the 
European Communities  in this sphere  and  in no  w~ commits  the Commission 
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Original 1 anguage  English INTRODUCTION 
Vaccination  programmes  are  especially  in  the  veterinary 
field  sometimes  very  contraversial subjects.  The  vac-
cines  and  vaccination  programmes  under  study  are  con-
cerned  about  three different diseases  in  the  three  for 
food  production most  important  domestique  species,  and 
they represent the whole  spectrum  of  differences  and 
contraversies  encountered.  Thus  it seems  reasonable  to 
conclude,  that if decisions  are  reached  concerning  these 
three  types  of  vaccines,  they  may  at the  same  type  pro-
vide  guidelines  for  other  veterinary vaccines  in  the  Mem-
ber States. 
As  a  general  introduction to  the  comparative  study  on 
rules  and  regulations it has  been  attempted  to give  a 
brief description of  the  main  problems  of  vaccine  pro-
duction  and vaccination.  The  general rules  for  the  con-
trol of sterility,  toxicity and  such  problems  are  not 
mentioned  in  the  study,  not  because  they  are  unimportant, 
on  the  contrary,  but because  they are  hardly subject to 
any  conflicting views  or  usages.  In  addition  there  are 
little differences  in  the  rules  for  most  vaccines  and 
rarely specific  for  the  individual vaccines. 
For  each  of  the  three vaccines  under  study  an  introduc-
tory  su~nary of  information  on  the virus,  the disease 
and  the  principle  types  of vaccines  are  given. 
Ebba  Lund -I-
1.  THE  GENERAL  PROBLEMS  OF  ACTIVE  I~1UNIZATION AGAINST 
VIRUS  DISEASES 
Active  immunization  against  infectious diseases  has  been 
practiced long before  knowledge  of  the  nature  of bacte-
ria and  viruses  was  available.  Empirically it was  found 
that by  transfering infection  from  one  individual  (man 
or  animal)  to the  other at a  stage  or during  a  period, 
where  the disease  seemed  to run  a  mild  course  or where 
the  individual  seemed  more  resistent to the disease  or 
its consequence,  one  might  obtain  immunization.  This  im-
munization might  be  obtained without disease  or at least 
without  any  serious  symptoms.  Even  to day  such methods 
are  employed.  The  obvious  risks  of starting an  epidemic 
by  spreading  the  infection further  from  the  intentionally 
inoculated  animals  or  of  having wrongly  interpreted the 
virulence  of  the strain so that even  the  incubated indi-
viduals  become  seriously ill cannot,  ho"~:vever,  be  elimina-
ted. 
More  systematic  attempts  to produce  vaccines  started in 
the Western world with Jenner,  who  in  1796  vaccinated 
against  smallpox by  the  use  of  cowpox  virus  produced in 
calves.  Pasteur,  who  applied vaccination  somewhat  more 
scientifically,  named  the process  vaccination after vacca 
(cow)  thereby  acknowledging  the  importance of Jenner's work. 
Vaccines  against viral diseases  are especially  important, 
because virtually no  therapy  against virus  infections 
exists,  but with  the  encreasing  tendency  towards  resi-
stance against antibiotics,  it seems  possible that vacci-
nations  against bacterial  and  protozooan diseases will also 
become  more  important than at present. 
Vaccines  should be  safe  and efficient,  should preferably 
be  effective  for  long periods  after vaccination with  a  mini-
mum  of boosters,  and  complications  should be  few.  Vaccines, 
which  ideally fulfill these criteria, hardly exist, al--2-
though  great progress  has  been  made.  The  first necessa-
ry condition fer  producing  a  vaccine  is that a  method 
for  the  isblation  and  cultivatioQ of  the  organism  in que-
stion exists.  This  is not  always  the  case.  In other situa-
tions it may  be  possible theoretically to produce  a  vac-
cine,  but practical  and  economic  considerations  may  make 
vaccinations quite unrealistic.  It is not  reasonably to 
consider vaccination  programmes  for  man  or animals  that 
include several hundreds  of virus  strains. 
Because  of rapid  genetic variations  in  some  virus  strains 
it will become  very difficult to carry out true profylac-
tic vaccination programmes.  It is very  inefficient to 
vaccinate  against last year's virus  strain if this year's 
strain is so different that there  is  no  cross-immuniza-
tion  possible between  the strains.  This  type  of problem 
may  arise in connection with e.g.  influenza of  man  and 
foot  and  mouth  disease. 
In  some  cases  vaccination  may  be  less efficient,  be-
cause  even  the natural infection causes  only transient 
protection.  With  present day  knowledge it is,  however, 
quite difficult to distinguish between  an  immunity  of  short 
duration  and  the  result of  a  situation,  where  many  diffi-
rent serotypes  of  a  virus exist,  such  that the  same  disease 
may  repeatedly  become  manifest in the  same  individual  but 
caused by different types  of virus. 
In  the  production of  microorganisms  to be  used  for  vac-
cines it is not  enough  that the  harvested material is  an-
tigenically potent.  Both  pathogenic  and  non-pathogenic  or-
ganisms  contain several antigens  that have  nothing to do 
with  the  provocation  of or protection against disease.  It 
is possible  to cultivate bacteria,  and  possibly also vi-
ruses,  in  such  a  way  that they  may  multiply1  but  have  lost 
the ability to  stimulate  protective  immunological  reac-
tions1  whether  the  immunization is  due  to the  forma·tion 
of  immune-globulins  and/or  functions  through  "cell-media--3-
ted"  immunity.  Thus  it is not  enough  that  a  product is 
antigenically potent,  it must  contain  the  right antigens. 
Consequently  although it is  very  important  and  useful  to 
have  a  number  of  serological  and  other controling me-
thods  for  the  evaluation of  the  potency of  a  vaccine,  ul-
timately  the  only  true evaluation remains  the  evaluation 
of  the  protective capacity of  a  vaccine,  estimated  through 
a  realistic challenge  experiment  employing  the  animals  of 
the  type  that should  be  protected.  All sorts  of  approxi-
mative  evaluations  may  be  obtainec by  employing methods 
giving  information  about  antigenicity and  other charac-
teristics, but  such  methods  can  only  serve  as  substitutes 
and  even  this  only  under  very  specific circumstances, 
which  must  be  evaluated most  carefully. 
In  a  few  cases  (e.g.  diphtheria  and  tetanus)  the  disease 
is almost  solely due  to the  production of  a  single  toxin. 
In  such  cases  the  vaccine  production  is  a  relatively simple 
matter,  as  it is possible  by  treatment with e.g.  formalin 
to detoxify  the  toxin without destroying its essential 
antigenicity.  Unfortunately,  in by  far the most  of the infec-
tions,virulence  of  the  pathogen  and  consequently also  the 
protection of  the  host  animal  is  governed  by  a  number  of 
factors,  some  of which  seem difficult to identify and  give their 
proper relative importance.  A  satisfactory vaccine  there-
fore  contains  a  mixture  of  components,  some  of which  are 
perhaps  not  necessary,  but  they  are  at least apparently 
not harmful. 
A  virus  in principle consists of  a  strand of nucleic 
acid containing the  infectious material  surrounded by 
a  proteinaceous material  of more  or  less  complicated 
structure that sometimes  contains  other substances 
(lipids  and  carbohydrates).  The  antigenicity  and  spe-
cificity towards  the host cell are  a  property of these 
outer parts.  Consequently  one  may  in principle operate 
with  three different types  of vaccine-preparations: 
l)  An  inactivated  (or  "killed")  vaccine,  which  is  a  sus--4-
pension of virulent 1  active virus 1  which  by  some  means 
(usually  chemical)  has  been  rendered  inact:i  ve  {is  "killed") 
to  such  a  degree,  that viable,  infective virus-particles 
are  no  longer demonstrable. 
2)  A'~ive:' attenuated virus  vaccine,  which contains  a 
suspension of infective virus particles that are not 
disease-producing if used properly. 
J)  Extract vaccines  where  the virus  suspe~sion is  frac-
tionated chemically  in such  a  way,  that the  nucleic acid 
component  is not present in the  vaccine  neither as  in-
fectious  nor  as  inactivated molecules.  The  vaccine  con-
tains,  however,  the  proteins  and  should have  full anti-
genicity~ 
1.  1.  K  i  1  1  e  d  v  i  r  u  s-v  a  c  c  i  n  e  s 
A  virus  suspension is produced  through  the harvest of  a 
material  from  animals,  embryonated  eggs  or  some  kind of 
cell cultures  which  previously  have  been  inoculated 
with  the  virus.  This  raw  suspension is separated in  a 
suitable degree  from  cellular components  etc,  and it is 
checked,  that the  amount  of virus  present is  large  enough 
so that the  suspension after inactivation con-
tains  a  sufficient amount  of antigen  to be  useful  as  a 
vaccine.  The  inactivation may  be  carried out by  means  of 
formalin,  beta-propiolactone or other  chemical means,  or 
physical methods,  such  as  UV  radiation,  may  be  employed. 
The  reaction is carried out,  at  a  certain  temperature  and 
employing  a  certain amount  of  the  compound  or treatment, 
so  that it may  be  deduced  from previous  experiments  that 
the virus  suspension is inactivated.  On  the  other hand 
the  reaction  cannot be  allowed  to  continue  for  so  long 
that the  antigenic  capacity is diminished in such  a  way, 
that  the  product is not  useful  as  a  vaccine. 
For  a  certain period in the history of  the  development  of 
inactivated virus  vaccines  disagreable  accidents  took 
place,  because  such  virus strains that were  especially 
virulent were  chosen  as  vaccine  strains on  the  assumption 
that in -5-
this way  the best antigens  were  also obtained.  As  vi-
rulence  and  antigenicity are not properties that are 
correlated,  all that was  obtained was  a  vaccine that 
was  potentially more  dangerous,  than if a  less viru-
lent strain had been  employed.  This  was  because  a  pos-
sible residues of active virus  left,  after the  inactiva-
tion period were still of the most  virulent type. 
The  testing of  a  vaccine is considerably  more  work-consu-
ming  and  exacting than  the production of the  vaccine. 
The  test work  contains  several  important steps. 
The  vaccine is tested in  a  specified way  to  show  that it 
can  immunize  suitable experimental  animals  (potency test). 
The  control  for different contaminants  is  a  relatively 
simple matter as  long  as  bacteria and  fungi  are  thought of 
but the  controls that must  be  carried out  on  the  cellular 
material  for  contaminating viruses  remain  a  complicated 
matter. 
Innocuity tests  for  residuals of active virus  in vac-
cines  may  present  a  statistical problem:  It is not  enough 
that  a  random  sample  of the proper size  from  a  certain 
batch  is without  demonstrable  amounts  of active virus. 
Only  if the whole  production has  been  found  equally sa-
tisfactory,  may  the single batch be  accepted.  It is sta-
tistically quite possible that  a  single batch out of  an 
unsatisfactory production  may  pass  the  accepted tests 
and still not  be  acceptable,  because  of  the probability 
that this batch  also contains  an  unacceptable  amount  of 
virus.  This  problem was  quite serious in the early years 
of polio vaccines. 
Even  if a  vaccine has  passed the different tests it is 
still possible that it may  contain  a  small  residue of 
active virus,  which  is under  the  threshold of the sensi-
tivity of the test for  innocuity.  If the whole  herd is 
vaccinated simultaneously this will not  cause  problems, 
but if single  animals  are vaccinated in  non-immune  herds 
the  virus  may  after a  number  of  animal  passages  be pro--6-
pagated  in such amounts  that overt disease is produced 
and  further transferred.  Corresponding  problems  may 
arise through unsuitable storage or wrong  dosing of the 
vaccine  so  that more  infectious virus is present in a 
vaccine dose  than was  intended  by  the producer. 
When  a  vaccine  has  passed all tests required  for  showing 
that it is properly inactivated and  contains sufficient 
amounts  of antigen,  the most  important test must  follow: 
Is it a  vaccine,  i.e. does it protect the animals against 
disease?  Not  too  long  ago it was  generally accepted that 
if antibody production could  be  provoked,  then protection 
would  follow  by  necessity.  It is now  accepted,  that  "im-
munity"  is a  heterogenious capacity,  and  that a  vaccine 
may  contain good  antigens,  but give poor protection.  On 
the other  hand  immunity  may  be  present on  a  cellular level, 
so  that an  individual may  be  protected against a  viral 
disease without  having demonstrable  amounts  of antibodies. 
It is usually accepted,  that an efficient inactivated 
vaccine may  protect,  but that the protection is of limited 
duration.  The  period depends  among  other things  on  the 
amount  of antigen  inoculated.  It is also accepted,  that 
even  a  modest  residual  immunity  may  be  boosted  by  a  na-
tural infection or revaccination. 
Apart  from  the problems  connected with  the possibility 
of  not  having  a  sufficiently inactivated vaccine various 
side effect of undesirable nature may  be  encountered. 
These  side effects are usually due  to sensitization,  so 
that hypersensibility reactions may  occur  in connection 
with revaccination.  Individual animals  may  also  show 
allergic reactions even at primary vaccinations  because 
of reactions against components of  the vaccine. 
1.  2.  L  i  v  e  v  a  c  c  i  n  e  s 
Live vaccines  have  advantages over  inactivated ones, 
because  by multiplication and  spread of the virus in 
the organism a  complete  series of protection-provoking 
antigens may  be  formed,  antigens which perhaps are not -7-
formed  in the  same  way  outside the whole  animal  body. 
There must  be  specific reasons  why  live vaccines are 
most effective in a  number  of cases where cellular 
immunity  seems  to play an especially important role. 
This is found  for  tuberculosis,  brucellosis and  a  number 
of viruses.  Present day  knowledge  of  immunology  is not 
sufficient to explain the mechanisms  involved. 
The  old  smallpox vaccine  by  Jenner  and all other pox vac-
cines are  live vaccines.  These vaccines are  examples of 
original field strains,  which  have  been very useful as 
live vaccines without  any  special manipulations.  In most 
cases live,  avirulent strains are obtained  by  attenuation 
through passages  in a  foreign  host,  so  that infectivity 
is preserved,  but virulence is lost for  the  normal  host. 
The  methods  employed  in this work  are totally empirical. 
The  necessary controls for  live virus vaccines are  usual-
ly still more  complicated than  the controls for  the  inac-
tivated vaccines.  Controls must  be  established to make 
sure  that the virus strain of  the vaccine does  not modify 
itself to the point of not being  infectious  for  the nor-
mal  host.  The  vaccine must also be  so  controlled that the 
strain through further passages  in the  foreign  does  not 
revert in the direction of the original,  virulent virus 
strain.  The  purity of the vaccine must  be controlled  so 
that the vaccine neither contains bacteria nor viruses 
released  from  the cellular material.  After that the 
protective capacity of the vaccine must  be  tested.  As 
the virus,  in a  number  of cases may  spread  from  the vac-
cinated individuals it is necessary as far as  possible 
to get an  idea of the genetic stability of the virus 
strain,  so  that spread through  several  individuals of 
the natural  host does  not result in the reversal of the 
attenuated strain to  a  more virulent form.  In  some 
cases  (e.g.  rabies vaccines)  it has  been  found,  that a 
virus strain may  be quite sufficiently attenuated for 
use  in one  species  (e.g.  dogs),  whereas  another  species 
(e.g.  cattle)  may  get the disease.  If a  vaccine contains  a 
strain of virus,  which may  infect several wild  and  domestic -8-
species,  then  careful consideration must  be  given  to 
whether it is advisable to let loose  a  virus  into  a 
reservoir of  animals  with  the possible result that  a 
disease is spread rather than  just getting an  extended 
immunization.  Such  a  disease  may  become  next to  impos-
sible to control. 
A  ~pecial problem is encountered in connection with vac-
cination of pregnant  animals  or vaccination with vaccines 
containing viruses,  which  may  spread  from  vaccinated in-
dividuals  to pregnant animals.  Any  virus  infection,  even 
such natural infections that normally  remain  subclinical 
or with minor  symptoms  may  be  serious  for  the early embryo. 
Therefore  even  an  attenuated virus strain,  which  normally 
gives  symptoms  of infection only  in the  rare case  and 
therefore  may  be  employed  as  a  vaccine,  may  give  problems 
in connection with pregnancies.  Malformations or embryo-
nic death,  generalized congenital or neonatal  infections 
may  result depending  on  the  time  during pregnancy,  when 
the  infection occurs. 
An  important  advantage  in the  use  of  a  live vaccine is 
that the natural  infection is copied to  a  much  higher de-
gree,  than  seems  possible in connection with  the  use of 
an  inactivated vaccine with  the result,  that the  chance of 
acquiring  a  long  lasting and  general,  cell-bound as  well 
as  humoral  immunity  is increased considerably. 
The  practical  and  economic  advantages  connected with  the 
use  of  a  live vaccine  are of  course  considerable  in all 
such  cases,  where oral administration or  a  spray prepara-
tion may  be  employed. 
Live  attenuated virus  vaccines  are often made with virus-
types  that are quite labile,  i.e.  then rather easily loose 
their infectivity  (e.g.  herpesviruses,  paramyxoviruses) 
and  therefore unsuitable handling  and  storage after the 
vaccine has  left the  producer  may  damage  the quality of 
the  live,  attenuated vaccine:  If the  virus  becomes  inactiva-
ted or partly inactivated then  no  active virus  or  an  inade-
quate  dose  to  "take"  is employed,  when  vaccinating  and  no 
immunization is obtained at all. -9-
Also  in connection with  the  use  of  live vaccine  hyper-
sensitivity reactions  may  occur,  e.g.  against substrate 
components  from  the  preparation,  but the  problems  seldom 
b  e co m e  serious  as  has  been  the  case with  some  inacti-
vated vaccines. 
By  chosing  the  p~oper dose  of  a  proper virus strain for 
the  vaccine  a  100%  take  could  theoretically be  expected. 
In  practical  situations  interference  phenomenons  may, 
however,  disturb  the  situation, because  natural,  but  in-
apparent  infections with  other viruses  may  interfere,  so 
that  no  take  is obtained with  the  vaccine  infection.  For 
this  reason  revaccinations  even with  a  live vaccine  may  be 
desirable. 
1.  3.  E  x  t  r  a  c  t-v a  c  c  i  n  e  s 
If  a  culture  fraction can  be  obtained  which  contains  the 
protection-provoking  antigens  and  no  allergens,  a  very  sa-
tisfactory vaccine  may  be  obtained ·from such  a  fraction. 
It has  been  possible  to produce  such  vaccines  against e.g. 
pertussis  and  other bacterial infections,  and  a  number  of 
experimental virus  vaccines  have  been  made.  From 
a  control point of  view  an  ideal situation arises,  if the 
antigens  and  the  infectious  nucleic  acid of  the  virus 
particles are  separated  from  each  other.  Unfortunately 
the  results  obtained with e.g.  measles  vaccines  have  been 
far  from  promising.  In spite of  the  fact  that these  vac-
cines  have  been  good  antigens,  stimulating the  production 
of  antibodiJs,  no  production  against natural infection was 
found.  On  the  contrary,  the  average  measles  case  in  the 
vaccinated children was  aggravated  compared with  the  ave-
rage  case  of  non-vaccinated children.  The  same  has  some-
times  happened,  when  inactivated vaccines  have  been  employed. - 10-
2.  THE  CONTROL  OF  THE  VIRUS  DISEASES  OF  THE  STUDY 
For  centuri~s the  control of  virus  diseases  of  dome-
stic animals  h:1s  been  of  mutual  interest to  a  number  of 
countries,  but  a  common  policy does  not exist,  not  even 
within  the  EEC.  There  are  permanent  threats  in all three 
types  of  infections,  but  the  ultimate  control  may  not  be 
achieved  in  the  same  way  in all the  cases.  The  proper 
procedure  may  depend  not only  on  the virus,  the  animal 
in question  and  the  epidemic  situation~ but also  on  the 
local economic,  social conditions,  traditions within  the 
agriculture  and  many  other things. 
In principle there  are  only  two  ways  of getting proper 
control:  l)  general  vaccination  programmes  or  2 )  eradi-
cation.  The  goal  should be  eradication,  because  in  the 
long  run  this  seems  the  only efficient way,  but vaccina-
tions  may  prove  to be  less  costly  and  most  valuable  for 
years  to  come.  With  the proper vaccines  the  incidence 
rate of disease  may  be  significantly reduced.  Irrespec-
tive of  the  ultimate  course  to be  followed  joint efforts, 
improved diagnostic methods,  standardization of procedures, 
the setting up  of  reference  laboratories etc are  the  ne-
cessary minimum  requirements  to be  satisfied to  approach 
the  ultimate  goal of control. - II -
3.  FOOT  AND  MOUTH  DISEASE  VACCINE 
3.  1.  I  n  t  r  o  d  u  c  t  i  o  n 
3.  1.  1.  Foot  and  Mouth  Disease Virus 
The  virus  of  Foot  and  Mouth  Disease  was  the  first animal 
virus  to  be  recognized  as  a  filtrable  agent  by  Loeffler 
and  Frosch  in  1897.  The  attempts  to vaccinate against  the 
disease  were  the  imnediate background  for  the  discovery, 
which  came  a  few  years  after the  first description of  a 
"filtrable agent",  the  Tobacco  Mosaic  Disease  in plants. 
The  size of  the  FMD  virus  is  around  25  nm,  and  the  virus 
consists  of  an  inner part of  infective nucleic  acid  of 
RNA-type  surrounded by  a  very  densely packed  shell of  pro-
tein subunits  symmetrically  arranged  around  the  nucleic 
acid strand.  The  virus  belongs tothe rhinoviruses  of  the 
picornavirus  group  ("the  small  RNA'J...viruses)  and  is  a 
stable virus  resistent towards  physical  inactivation such 
as  heat  treatment,  especially in  the  presence  of  high  con-
centrations  of  organic material.  The  virus  is easily 
destroyed both at high  and  low  pH  values. 
There  are  7  serological  main  types of  FMD  virus  known: 
The  A,  0  and  C  types,  whi6h  are  usually  included  in  the 
trivalent vaccines  employed  in Europe.  These  three  types 
are widely  spread.  The  South  African  strains,  SAT  1,  2 
and  3  were  found  only  in Africa until  1962,  when  SAT  1 
spread  to  the  £1iddle  East  and  the  European  Turkey  in  1962. 
Within  the  individual  major  groups  new  subgroups  are  oc-
curring.  This  makes  the  inclusion of  new  subtypes  in the 
vaccines  necessary  from  time  to  time.  The  Institute at 
Pirbright is  a  World  Reference  Laboratory  for  the  typing 
of strains. - 12-
3.  1.  2.  Foot  and  Mouth  Disease 
(Synonum:  Aphtous  fever) 
A  huge  number  of publications  have  appeared  on  the  sub-
ject,  Brooksby  (1958)  and  Bachrach  (1968)  have  published 
literature reviews. 
The  disease  in cattle is usually not  fatal,  but  leads  to 
loss of condition  and  consequent  economic  loss.  Fever 
and vesicular eruptions  on  mouth,  tongue,  muzzle,  hooves 
and  udder are  characteristic symptoms.  Sometimes  lameness 
occurs.  This  symptom is prominent  in pigs.  Sheep,  goat, 
deer,  antilopes  and other  ruminants  as well  as  pigs  may 
become  infected.  A  number  of  small  laboratory  animals 
may  become  infected experimentally. 
The  disease  is extremely  contagious  by  direct and  indi-
rect contact as  well  as  by  airborne dissemination.  Un-
cooked  meat  and  garbage  may  be  a  source of infection. 
The  infection may  be persistant for  several months,  and 
some  animals  may  become  cronic carriers.  Australia,  New 
Zealand,  U.S.A.  and  Canada  are  free  from  the disease. 
The  infection is endemic  in parts of Continental Europe, 
in Asia,  Africa  and  in South  America. 
3.  1.  3.  Control 
Where  the  disease  is not  endemic  a  policy of quarantine 
and  slaughter may  be  an  efficient and  economically sa-
tisfactory means  of control.  However,  in  some  areas  the 
slaughter policies  are  supplemented with  the  use  of in-
activated vaccines.  In  endemic  areas  the  use  of  formalin 
or acetylethylenimine inactivated vaccine with proper 
adjuvantia is  commonly  used.  The  raw  material  for  a  vac-
cine is either epithelia  from  tongues  of infected cattle 
or  some  sort of cell cultures  prepared  from  primary tis-
sues  or  from established cell lines. 
A  number  of countries  employing  compulsory  vaccinations 
have strict rules  about  accepting only  imports  of vacci-- 13  -
nated  cattle in order to protect the  local cattle.  If 
the  import is  from  a  FMD  free  area this  requirement  may 
not be  very  useful  as  a  safeguard.  It might  even be pos-
sible,  that the  vaccinated cattle occasionally represent 
a  certain risk not present in the  unvaccinated cattle. 
Accidents  have  occurred when  the vaccine  had not been 
properly prepared or tested.  Import  from  areas with  com-
pulsory vaccination,  which  may  mask  or alter a  FMD  virus 
infection may,  on  the other hand,  constitute real risk, 
but only if FMD  is present in the  area. 
Attenuated live virus  vaccines  have  been prepared by 
passages  in mice,  cell cultures or in eggs.  The  results 
of  such  vaccinations  have  varied in field trials and  such 
vaccines  are  in general considered too  dangerous  for  ge-
neral use  because  of the wide  host  range  of the virus. 
F.M.D.V.  Review  References: 
Brooksby,  J.B.  (1958)  Adv.  Virus  Res.  5,1. 
Bachrach,  H.L.  (1968)  Ann.  Rev.  Microbiol.  22,  201. - 14-
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3.  2.  L  e  g  i  s  1  a  t  i  on 
f  o  r  FMD  v  a  c  c  i 
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A  r  e  v  i  e  w  o  f  t  h  e  r  e  1  e  v  a  n  t  d  o  c  u-
m  e  n  t  s 
Belgium 
"  Arrete royal  du  3  avril  1965  relatif a  la lutte centre 
la  fi~vre aphteuse. 
Denmark 
Apotekerloven af Juli  1962  (The  Drug  Act  of  July  1962). 
Important  exceptions  are  granted  for  products  from  the 
State institutes.  New  legislation in preparation  (Lov 
om  l(P.gemidler),  but  no  essential principles  seem  changed. 
From  the Ministry  of  Agriculture  there  is  Lov  om  vacci-
nation mod  mund- og  klovesyge  (Act  on  vaccination 
against  foot- and  mouth  disease)  March  1960  and 
Bekendtg¢relse  om  vaccination mod  round- og  klovesyge 
(Order  on  vaccination against  FMD)  Nov.  1960. 
France 
""  Controle officiel des  vaccins  antiaphteux 
''\ 
(Arrete du  8  juin  1965  J.  Off.  29  juin  1965). 
Arr~te portant modification  de  l'arr~te du  8  juin  1965 
re1atif au  contro1e  officiel des  vaccins  antiaphteux 
(J.O.  31  decembre  1965). 
~  ~ 
Arrete du  2  juin  1971 relatif au  controle officiel des 
vaccins  antiaphteux. 
Germany 
3.  Verordnung  zurn  Schutz  gegen die  MKS  von  29.1.71 
einschliesslich der  Anlage  uber  die  Impfstoffe. 
Verordnung  uber  Sera  und  Impfstoffe  nach  §  170  des 
Viehseuchegesetzes  vorn  27.2.73. 
Ausfuhrungshinweise  zur  Verordnung  vorn  27.2.73. 
Richtlinie  fur die staatliche Prufung  von  Maul- und 
Klauenseuche-Vakzinen  (Juni  1973). - 15-
The  paragraph  7  was  modified  on  July  2,  1974. 
(The  rules  of  the  4.  rev.  of  the  pharmacopea  commis-
sion is not  agreed  upon  by  the  Germans). 
Holland 
The  legislation is the  responsability of  the Veterinary 
Department.  Contrary  to all other  veterinary  vaccines 
the  FMD  vaccine  is produced  and  controled by Centraal 
Diergeneeskundig Institute in  a  special department  in 
Lelystad. 
Ireland 
The  Therapeutic  Substances  Act  of  1932  has  no  veterinary 
equivalent. 
Animal  Remedies  Act  1956. 
Diseases  of  Animals  (Disinfection)  Order  of  1931. 
Italy 
L.  Ravaioli,  z.  Orfei  and  M.  Granieri: Controllo dei  sieri, 
dei  vaccini  e  dei  prodotti diagnostici  per  uso  veterina-
rio Istituto superiore di  sanita.  Laboratori  di Veterina-
ria.  Roma  1964. 
Ordinanza Ministeriale  7  luglio  1972.  Profilassi vacci-
naleobbligatoria  'dell'afta epizootica. 
Normes  por  le  contrdle  du  vaccin  antiaphteux en  Italie. 
Bull.  Off.  int.  Epiz.  (1972),  77,  1143-1147. 
Declared  intensions  to  follow  the  European  Pharmacoposia 
Commission  PA/PH/Exp.  15V/T  (70)12.  4th  revision  of 
12  April  1973,  also Legge  a  23  Giugno  1970,  n  503  Ordi-
namento  degli  Istituto Zooprofilattico sperimentale. 
11  Marzo  1974,  n  101  Modifica  delle  legge  23  Giugno  1970, 
n  503  sull'  ordinamento  degli istituti Zooprofilattico 
sperimentale. 
By  this  law  the  institutes of Torino,  Brescia,  Padova, 
Perugia,  Roma,  Teramo,  Portici  (Napoli),  Foggia,  Palermo 
and  Sassari  are  research  institutes doing  general  diagno-- 16-
stic work  under  the  supervision of  the Ministry of 
Publ.  Health  for  particular problems.  - Local  problems 
are dealt with  by  the  regional  Public Health Author.The 
division of  responsability is not  always  well  defined. 
Luxemburg 
Follow  Belgian rules. 
U.K. 
Medicines  Acts  1968  and  1971. 
The  Medical  Act  1969. 
Guide  to  the  Licensing System,  prepared by  the  Dept.  of 
Health  and  Social Security  on  behalf of  the  Health  and 
Agriculture  Departments  of  U.K.,  1972. 
Notes  on  applications  for  Product  Licenses  for veterinary 
medical  products,  prepared by  the Ministry  of Agriculture, 
Fisheries  and  Food  on  behalf of  the  Health  and  Agricul-
ture  Departments  of  the  United  Kingdom. 
All  vaccines  are  controlled under  the  Medicines  Act. 
Regulations  can  be  laid  down  for  individual vaccines,  but 
have not  been  for  FMD. - 17-
3.  3.  P  r  o  d  u  c  t  i  c  n 
3.  3.  1.  Identification of  the  Producer 
Belgium 
Only  the  State Laboratory  (Institut national de  Recher-
ches  veterinaires)  may  produce.  All  otheJ  products  are 
forbidden  including  imports. 
Denmark 
The  State Vet.  Institute for  Virus  Hesearch  produces  the 
vaccine  and  handles  the  viruses  in question.  The  ministry 
of Agriculture  may  decide  on  imports  of  vaccines. 
France 
Any  producer who,  after application  to the ministry  of 
agriculture  and  on  the  base  also  of  tests  of  a  prelimi-
nary  lot of  vaccine,  has  obtained  an  authorization  to 
produce  a  vaccine  may  do  so.  The  rules  and  the criteria 
for  the  production  and  vaccine  are  specified in details 
in  the  legislation  and  the  rules  are  such  that  as  a  matter 
of  fact  few  institutes  could  manage  to  produce. 
Germany 
A  producer who  has  obtained  a  permission  according  to 
the  legislation  (§  7  and  8).  Each  batch must,  however, 
be  controled  and  released by  the AJthorized State In-
stitute. There  are  at present  3  producers:  Behringwerke, 
the  German  Wellcome  and  Bayer  AG. 
Holland 
Only  the  State Laboratory 1  the  Centraal  Diergeneeskundig 
Institut  has a  governmental  license  to produce. 
Ireland 
There  is  no  Irish production. 
Imports  would  be  by  permission of  the  Department  of  Health - 18-
(after consultation with  the  epartment  of Agriculture), 
but  a  license has  never  been  issued. 
Italy 
The  Institutes  (Public  institute directly under  the 
ministry)  auth~rized by  the State.  At  present  4  such 
institutes  are  in principle producing,  but in very 
different  amounts. 
Luxemburg 
No  production. 
U.K. 
At  the  Animal  Virus  Res.  Inst., Pirbright,  a  stock  of 
vaccine  is held.  The  only  licensed producer  is situated 
at this institute,  and  no  one  else is  allowed to handle 
the virus.  The  vaccine  has  never  been  used. 
Summary: 
The  situation in  the  individual  Merooer  States is  summa-
rized in table  1.  As  may  be  seen  three  categories exist: 
No  production  (Ireland),  production by  licensed private 
firms  (France  and  Germany)  or by  a  State Laboratory 
(Belgium 1  Denmark,  Holland,  Italy  and  U.K.). - 19-
Table  1.  Foot- and  Mouth  Disease Vaccine  for  Cattle 
Schematic presentation of  FMD  vaccine  use 
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3.  3.  2.  Licenses  for  Establishment 
Belgium 
As  only  the  In~titut National  de  Recherches  veterinaire 
may  produce  thare is no  special license  system. 
Denmark 
Although  no  legislation specifies this,the Vet.  Auth. 
actually  through  their right to distribute the vaccines 
employed,  control  production so that only  the Veterinary State 
Institute for Virus  Research  produces  vaccine. 
France 
Legislation prescribes  that after approval  of  premises 
etc and  tests carried out  on  a  preliminary  lot,  an  autho-
rization to produce  may  be  obtained  from  the State.  The 
rules  are quite detailed.  The  product must  be  tested in 
~  1  2  bovines  and  have  a  K-value  (see  later)  of  -10  ·  • 
Germany 
Although  the  legislation concerning  production control 
since  1973  prescribes  that the  sample  taking  and  testing 
is done  by  the State,  it is still up  to the  Regional 
(Lander-)  Government  to issue establishment  licenses. 
Holland 
No  special  license as  the  State Lab.  is the  only  one 
permitted  to produce. 
Ireland 
No  production  of vaccine. 
Italy 
The  Publ.  Inst.  are selected and  authorized by  the Mini-
stry,  but  the  Regional  Publ.  Health Authorities  have  in-
fluence,  at present Istituto zooprofilathico sperimen-
tal della Lombardia  e  dell'  Emilia  (Brescia)  and  the - 21-
corresponding institutes in Teramo,  Perugia,  Padova  and 
Torino are  authorized,  but most  of  the  vaccine is pro-
duced  in Brescia. 
U.  K. 
Licenses  are  issued  for  veterinary products  by  the Mini-
stry of Agriculture,  Fisheries  and  Food.  The  FMD  vaccine 
production is the  responsibility of  Pirbright~ but  the 
general principles  laid down  in ·the  Licensing  system 
must  be  followed~ and it is in fact  the  Wellcome  Founda-
tion,  who  produces. 
3.  3.  3.  Licenses  for  Release 
Belgium 
No  special  license  as  only  the State lab.  produces. 
Denmark 
The  same  as  for  Belgium.  The  Vet.  Authorities  are  de  facto 
releasing  through  their distribution of  the  vaccine. 
France 
All  lots of vaccine whether  produced  in France or  impor-
ted  (through  a  permission given  to  a  French  laboratory) 
are  tested in  the  finished state and  on  minimum  lots of 
50,000  doses  of  trivalent vaccines.  The  producer  must 
request,  that samples  be  taken.  The  producer of  a  batch 
of  vaccine  may  at his  own  responsability release  the  vac-
cine,  if he  has  not received  a  test result after  50  days. 
The  controling lot may  permit  the  use  of  the  vaccine be-
fore  the  results  are  obtained  from  the  tests~ if the pro-
tocols  of  the  producer  show,  that  the  vaccine  is better 
than  the quality required in  the official test  (this  ap-
plies only  to the  period Jan.  1  to April  30). 
Germany 
The  authorized State Institute releases  the  individual - 22-
production batches.  According  to  the  legislation the 
Authorized  Lab.  must decide if the vaccine is actually 
tested by  authorized  Institute,  or if the tests carried 
out by  the producer according to protocols are suffi-
cient,  but  the official testing as  such is compulsory. 
The  rules are  commented  and  further elaborated  in the 
"AusfOhrungshinweise".  There  are  a  number  of rules 
concerning  the  rooms  etc.,  also about  who  is sampling 
and  what  samples  are  taken  and  kept,  the protocols of 
production and  other relevant subjects.  If considered 
necessary because of the epidemiological  situation, 
the Ministry of Agriculture may  deviate  from  the  normal 
control rules. 
Holland 
Same  as  for  Belgium and  Denmark;  no  special  licence 
required  and  the State Lab  produces  the vaccine. 
Ireland 
The Vet.  Auth.  may  decide on  imports  and  this would 
in principle correspond to a  release license. 
Italy 
Batches of one million doses of trivalent vaccines are 
licensed  by  the  · Istituto Superiore di Sanita after 
the prescribed tests have  been carried out. 
U.  K. 
The  vaccine would  be  released  by  Pirbright,  but has 
actually never  been used. - 23-
3.  4.  C  o  n  t  r  o  1  1  i  n  g  A u  t  h  o  r  i  t  i  e  s 
Belgium 
The  producer  (the State Laboratory). 
Denmark 
The  producer  (the State Lab.). 
France 
Two  State Institutes:  Le  laboratoire central de 
controle et de  recherches  du  service  v~t~rinaire a 
Alfort et le laboratoire de  virologie animal a Lyon. 
In Lyon  a  scheme  is decided according to which  the 
individual  samples  are distributed between  the  two 
laboratories. 
Germany 
The  State through  the Bundesforschungsanstalt der 
Viruskrankheiten in Tubingen. 
Holland 
The  producer  (the State Laboratory). 
Ireland 
No  production or control. 
Italy 
In principle The  State,  but through different organi-
sations than  the producing institute.  Some  tests such 
as  serum neutralization tests may  be carried out in 
the  Istituto Superiore di Sanita in Roma,  but the 
challenge tests are carried out  in the producing in-
situte under  close supervision  by  one representative 
from  Direzione Generale Veterinaria Ministero della 
SanitA.  The  Torino institutes have  their cattle tests 
carried out in Brescia,  the Institute of Padova  in Teramo. - 24-
U.  K. 
On  ·behalf  of  the Ministry  of  Ag~iculture, Fisheries  and 
Food  the A.V.R.I.,  Pirbright,  is testing the  U.K.  stra-
tegic  reserve  ... - 25-
3.  5.  T  h  e  C on t  r  o  1  s  a  n  d  S  t  a  n  d  a  r  d 
r  e  q  u  i  r  e  d 
3.  5.  1.  General  Rules 
Belgium 
No  specific recommendations,  bu  the  control is  made  ac-
cording  to  the  OIE  and  FAO  standards. 
Denmark 
No  general rules  stated. 
France 
Rules  are  given both  for  the  tests that should be  car-
ried out by  the  producer  and  for  the official testing. 
A  number  of  physical-chemical  and sterility tests etc. 
are  also stated.  The  rules  for  sampling  are  very  con-
cise  and  detailed. 
The  regulations  concerning official testing of  FMD  vac-
cines  in France  (Order  8  June  1965  with  annex  and  inter-
/·. 
pretation)  were  published  by F.  Lucam et. al.  (Le  Controle 
officiel  fran~ais des  vaccins  antiaphteux)  in the  OIE 
Bulletin vel.  65,  No.  3/4,  pp.  385-418,  1966.  The  Order 
8  June  1966  was  modified by Order  2  June  1971  (Journal 
Officiel No.  5590,  10  June  1971). 
Details of testing procedures  and  statistical interpreta-
tion of results  as  applied in Lyon  are  given  in  "Le  con-
trc;le  des  vaccins  antiaphteux  inactiv~s" published by 
J. Fontaine et al.  in  Revue  Med.  Vet.  vel.  122,  pp.  289-321, 
1971. 
Germany 
A  number  of rules  for  sampling,  sample  size,  sample  storage 
etc.  are  given.  The  specifications  for purity tests are 
given.  The  in-plant tests carried out by  the  producer are 
apparently not stated in  the  legislation except  through  the - 26-
general  rules  for vaccine production.  These  rules 
are very detailed.  So  far  the  Germans  do  not agree 
with the tests suggested  in the  Pharmacopoeia  Commis-
sion.  It is specifically stated,  that the vaccine may 
be  produced  in calves,  in Frankel cultures or  in cell 
cultures  from calf kidney or  BKK  cells. 
Holland 
The  vaccine is produced  in Frankel cultures.  The 
protocol  for  the testing stays within the  producing 
department.  No  general rules are stated. 
Ireland 
No  production. 
Italy 
The  required vaccine  standards as  to sterility and 
purity,  container quality and  labeling are expressed 
in the rules  from  1964. 
The  rules  from  1964  differ from  the  "Norme  pour  le 
contr8le-"  1972.  The  controls  and  standards official-
ly required  by  the State are the ones of  the publica-
tion from  1964,  but both the control  lab.  of  Istituto 
Superiore di Sanita,  Roma,  and  the producing institutes 
are in general doing better than that,  and  the  "Norme"-
publication of  1972  is followed. 
U.  K. 
No  general rules are stated for  the official acceptance 
tests or for  the batch testing by  the producer. 
3.  5.  2.  Innocuity Tests 
Belgium 
Testing is carried out on  three groups of three cattle - 27-
each.  The  first group  receives  the vaccine contained 
in one bottle at the beginning of the bottling process, 
whereas  the  second  receives  the vaccine  from  one 
bottle in the middle  and  the third group  receives  the 
vaccine of the last bottle. 
In each group,  one  animal  receives one  dose  of vaccine 
by  intramuscular injection and  one  dose  intradermolin-
gually. 
The  other  two  animals  are vaccinated regularly with 
one  dose of vaccine injected into the  dewlap.  The 
animals are kept under observation for  three weeks. 
Denmark 
A.  Tests  in mice:  8  litters of  baby-mice  (2-4  days old) 
are inoculated intraperitoneally.  Dose:  0.1 ml  per 
baby-mouse.  This  examination is passed if none  of the 
baby-mice dies within the first six days. 
B.  Tests  in cattle:  Three  susceptible heifers,  of 
which  the  body-temperature is controlled,  are  inoculated 
intradermolingually.  Each  animal  is given  2  ml  of  the 
vaccine  injected at 10 different sites in the middle 
third of the  tongue.  Every  second  day  the  body  tempe-
rature is measured  and  two  weeks  after the  inoculation 
a  careful  inspection of mouth  and  feet is made.  If 
wounds,  scars or other abnormalities are not  found  on 
the  tongue,  gingiva,  palate as well  as  between  and 
around  the  hooves,  the vaccine is declared  safe. 
France 
The  vaccines must  be  incapable of producing  FMD  irre-
spective of  the way  it is used,  and  may  not produce  any 
pathological condition,  when  correctly used.  The 
finished product is tested employing heifers  from 
areas of Brittany.  The  vaccine may  not produce ve-
sicles where cattle have  not  been vaccinated.  The 
vaccine must  not produce vesicles or any other important 
pathological manifestations. - 28-
The  tests by  the producing institute for monovalent 
vaccines  (dose  1  ml)  on all batches are:  Tests on 
primary cells of pig kidney for cytopathic effect; 
tests on cattle with the completed vaccine  (Method  of 
Henderson);  injection  (intradermolingual)  of at least 
2  ml  of vaccine,  distributed over  20  points of the 
tongue,  of  2  or  3  cattle;  subcutaneous  inoculation 
of  5  ml  of vaccine  (3  doses). 
Trivalent vaccines  (dose  5  ml).  The  mixtures of tri-
valent vaccines are prepared  from monovalent vaccines 
tested on cells and cattle.  An  innocuity test in 
cattle is carried out on all batches according  to  the 
same  method as  the one carried out with monovalent 
vaccines,  however,  trebling the  injected doses. 
The  tests are carried out  by  the official controller. 
Only  the batches of trivalent or monovalent vaccines 
which are ready for  sale are tested officially.  The 
vaccine is tested in calf kidney cells for  cytopathic 
effect and  is tested in cattle by  a  method  similar to 
that applied  by  the producing  institute. 
Germany 
Testing  for  innocuity and  potency are  - with  the 
exception of  serological tests - carried out in the 
plant of the producer or  in  some  other place considered 
suitable by  the  testing institute.  The  tests must  be 
carried out in the presence of the official controller. 
Innocuity testing is carried out  for  infectious virus 
and  tolerance. 
The  test for  infectious virus is carried out in cattle 
(maximum  age  2  years),  which do  not  show  any  signs 
of disease,  and  which  are  free  from  neutralizing anti-
bodies against  FMD  virus.  It is assumed,  that cattle 
are neither affected  by  nor  immunized  against FMD,  if 
the neutralization titre is smaller  than 1:4. 
The  vaccine is tested in  3  heifers by  intradermolingual 
inoculation employing  5  ml  of vaccine  and  also  0.1  ml - 29-
inocula of a  concentrated  (1:60)  eluate  from  3  1  of the 
vaccine.  After  4  days  a  4-fold dose of the concentrated 
eluate is given  subcutaneously  (at least 20  ml).  In 
addition the vaccine is tested in cell cultures in a  pre-
scribed way.  Only if neither animals  nor cell cultures 
react to the inoculation,  the vaccine may  be  accepted. 
The  vaccine must  be  rejected if the general reaction in 
one or two  animals vaccinated in the potency test is so 
strong,  that the health is considerably  impaired,  or when 
local reactions at the point of vaccination in one or 
more  animals  exceed  the usual pattern,  and  such findings 
are confirmed  in subsequent trial vaccinations  in the 
same  number  of animals. 
Holland 
The  innocuity of each batch is ascertained  by  injection 
into Irish steers.  The  number  of animals  depend  on 
batch size  (5  steers for  a  2.000  1  batch).  Each  animal 
receives about  5  ml  of vaccine  by  means  of multiple 
intradermolingual injection.  After three days  they 
receive an additional  20  ml  intramuscularly.  The  animals 
are observed  for  10  days.  Temperature  is measured  twice 
daily.  Thereafter,  they are autopsied.  Tongue,  mouth, 
feet  and  rumen  receive special attention. 
Italy 
The  in plant innocuity test is done  in mice  for  the 
weekly batches.  The  official testing is done  according 
to the French rules by  intradermolingual  inoculation of 
0.1 ml  of vaccine each into  20  different sites on  the 
tongue of  15  months  old cattle.  Four  days  later, if no 
lesions have  been observed,  the vaccine is injected into 
the normal route,  but as  a  treble dose  into the  same  animals. 
U.  K. 
Initial tests are made  by  the manufacturers  on  the  inac-
tivated unformulated antigens,  using  a  tissue culture 
technique.  Six aliquots of  25  ml  of each antigen  suspen-
sion are tested for  the presence of infective virus in 
Roux  bottle cultures of  BHK  21  cells.  If cytopathic effects 
are not observed,  the  same  volume  of each culture medium - 30-
is  further  subcultured into  two  fresh  cultures.  In all, 
a  total of  three  subcultures  is r;1ade. 
Antigen  sus  pen~:; ions  which  have  passed the  tissue culture 
test are  blended and  vaccine  is  formulated  by  the  incorpo-
ration of  adjuvants.  The  innocuity test in cattle is made 
on  the  final  product.  Three  cattle  (Devon  or  Devon  x 
Shorthorn  steers~ 18-24  months  of  age)  are  inoculated 
with  the  vaccine  by  intradermal  lnjection at multiple 
sites  on  the  tongue.  Rectal  temperatures  are  taken  and 
the  tongues  and  feet  of  the cattle are  examined  periodi-
cally for  a  total of  10  days.  Provided  no  lesions  asso-
ciated with  virus  growth  are  observed,  the  vaccine  batch 
is  accepted  as  innocuous. 
3.  5.  3.  Potency  Tests 
Belgium 
Six cattle are  vaccinated per dose.  Requirements:  total 
absence  of generalization  lesions  during  the  15  days 
following  challenge  (10,000  bovine  ID5  intradermolingual-
ly).  The  activity of  the  vaccine  is evaluated by serolo-
gical methods. 
Denmark 
a)  20  guinea pigs  are  given  each  1  ml  of  vaccine  subcu-
taneously.  Three  weeks  after vaccination  a  challenge  dose 
of  103  guinea pig  ID50  of virulent virus  is given.  Gene-
ralized disease  should  be  prevented in  the  vaccinated ani-
mals  with  typical disease  in  the controls.  If 10  or more 
of  the  vaccinated animals  are  free  from  secondary  lesions 
the  vaccine  has  passed the test. 
b)  4  heifers  are  vaccinated subcutaneously  using  10  ml 
of  vaccine.  After  3  weeks  blood  samples  are  drawn,  and 
the  serum titre determinated  in cell cultures  and  in mice 
against  1500  rn50. 
The  vaccine  is  registered according to the  serum titre 
obtained in  the  following way: - 31-
Titre in cell cultures  >  - 32  8- 32  ~  8 
- - mice  ~ 128  32-128  <  32 
Vaccine quality  I  class  II class  not to be 
employed 
Challenge experiments  on  the  4  vaccinated heifers are 
carried out  3  weeks  after vaccination employing  a  concen-
tration of  104  mouse  Io50;ml of virus.  Two  heifers are 
tested with  intradermolingual  inoculation of a  0.25  ml 
virus and  two  by  rubbing  their tongues  with  a  virus 
drenched  pad of cotton.  The  animals are kept under ob-
servation for  two  weeks.  The  virulent virus is controlled 
by  titrations in mice,  not in cattle,  in order to mini-
mize  the  spread of virulent virus.  The  challenged ani-
mals  should  remain  completely free  from  generalized 
infection  (secondary  lesions). 
France 
Potency tests carried out  by  the producing  institute 
(for monovalent vaccines):  After  a  satisfactory innocuity 
test the protective dose  50%  is established in guinea 
pig  {Po50)  for all batches of vaccine.  The  vaccine 
dilutions are made  in buffer,  without adjuvant. 
For  each series of monovalent vaccines  (say  4  to  6 
batches),  produced  under  the  same  conditions,  the  PD50 
{cattle PD50 >  is established.  15 cattle are vaccinated, 
i.e.:  5  with one vaccine dose,  5  with 1/4 of the dose 
and  5  with 1/16 of  the dose,  the dilutions being  made 
with buffer without adjuvant. 
Three  weeks  later,  10000  I.U.  of fully virulent virus 
are inoculated  in the vaccinated animals  by  the intra-
dermolingual  route in two  points.  After  5  to  6  days 
the animals are slaughtered;  the primary  and  generalized 
lesions will  then  be  registered.  The  potency in cattle 
{number  of cattle Po50)  referred to one  dose of vaccine, 
is then calculated according  to the Probits method. 
Only  those vaccines which  have  a  PD  >5  are used  for  the 
preparation of trivalent vaccines. - 32-
The  antibodies  of cattle vaccinated with  1  full  dose  are 
then titrated by  serum-neutralization 
Trivalent  vaccj_nes 
For  each  series  of  vaccines  (4  to  8  batches)  prepared 
with  tested monovalent  vaccines,  the  PD50  is established 
for  one  batch.  The  method  is identical to  that employed 
for  monovalent  vaccines~  the  only difference being:  that 
the  volume  of  the  dose  is  trebled. 
The  antibodies of the  animals  are titrated for  each of 
the  three valences,  by  serum-neutralization. 
Potency  test carried out  by  the official  controller~ 
Generally  trivalent vaccines  are  submitted  to  testing. 
Only  those  monovalent  vaccines  are  tested which  are 
destined to be  marketed  as  such. 
First test:  Establishment  of  the  C  index  in  guinea  pigs. 
tthe  logarithm of  the~ndex between  the  virus titre in 
vaccinated guinea  pigs  and  the  virus  titre in unvaccina-
ted  guinea  pigs).  Four different levels  of  virulent virus 
a:-:e  'Ised  and  24  animals.  The  vaccine  is  acceptable if 
C  ~ 2.  In  such  cases  the  cattle test may  be  omitted  for 
batch  control. 
Second  test:  Establishment of  the S index  in calf kidney 
cells  (serum-neutralization test).  The  serum  from  the 
vaccinated heifer is tested in o.l ml  amounts  against  50  ro50 
of virus  produced  in cell cultures.  If the  S  value  obtai~ed 
is more  than,  or equal  to~ 1.5  for  ~  batch control,  the  K 
determinations  may  apparently be  omitted. 
Third test:  Establishment  of  the  K  index in cattle  (The 
logarithm of  the  index  between  the  virus  titre in vacci-
nated heifers over  the titre in unvaccinated  heifers~ The 
unvaccinated heifers  are  read  on  day  1  after inoculation 
and  the  vaccinated  on  day  2  after inoculation.  The  K-value, 
when  employing  a  high titre of  virus  should  be~ 1.2  for - 33-
a  class  I  vaccine,  if 1.2> K>  o.6  the  vaccine is class II, 
and  if K f::: o. 6  the  vaccine is rejected.  Only  5%  of  a  vac-
cine production  may  fall in class II. 
Germany 
Healthy cattle free  from  previous  contact with  FMD  are 
used  (three test animals  and  one  control  animal). 
The  vaccine  has  to be  administered to test cattle in the 
form  and quantity  as  foreseen  in  the directions of the 
producer;  the control  animal  is not  to be  vaccinated. 
The  test and  control  animals  are  to be  observed  for  at 
least  14  days.  During this period they  have  to  be  kept 
in such  a  wav  as  to  exclude  any  possible  FMD  infection. 
On  the  15th  day  at the earliest or on  the  21st  day  at the 
latest post-vaccination each test group  has  to be  stabled 
separately  and  challenged with  FMD  virus  Types  0,  A  or  C. 
The  selection of strains is the  task of the testing in-
stitute.  The  challenge is carried out by  intensive  rubbing 
of the  tongue,  the  muzzle  and  the nostrils of the vacci-
nated animal with  a  cotton  cloth.  The  cloth  (about  30  em 
by  30  em)  is  soaked  in  a  suspension  of  the  corresponding 
virus  types with  a  minimum  infection titre of  104LD50/ml 
for  unweaned  mice;  at least  75  ml  of the virus  suspen-
sion  are  to be  used  for  soaking the  cloth.  The  soaking 
has  to be  repeated for  each  animal  and  the  control  animal 
is treated in the  same  way.  The  animals  have  to be  ob-
served for at least  10  days.  Every  day  the  body  tempera-
ture has  to be  taken.  On  the  tenth  day  post-infection,  the 
animals  must  be  slaughtered.  An  exact anatomo-pathological 
examination has  to be  made  of the test and  control cattle; 
the  examination  has  to  refer in particular to specific 
abnormalities  on  the  tongue  and other parts of the oral 
cavity,  the  muzzle  and  the hoofs. 
The  control cattle must  contract generalized disease, 
(appearance  of vesicles  in  animals  under  test).Virus  re-
covered  from  the  vesicles must  accord in  type with  the 
innoculated virus  as  established by  complement  fixation. - 34-
If the  reaction appears  to be  caused by  a  virus  type 
other than  the  one  used  for  challenge or if generaliza-
tion did not  come  forth both  in  the test animals  and  the 
controls,  challenge is to be  repeated with  the  same  virus 
type. 
In  the  case of accordance  between  vaccine  and  challenge 
virus  type: 
a)  the  test has  to be  repeated if 1  test animal  has 
generalized or  two  and  more  test animals  have  shown  pri-
mary  vesicles  in the oral cavity, 
b)  the  vaccine  is to be  rejected if two  or more  test 
animals  have  shown  generalization. 
In  the  case  that according to the  letter  (a)  testing is 
repeated,  the  number  of  the  animals  in one  test group  must 
be  doubled.  After repetition of  the test,  the  vaccine will 
be  rejected if: 
one  or more  test cattle  came  down  with generalized disease 
or if: 
three or more  test cattle showed  primary  vesicles  in the 
oral cavity. 
Instead of testing cattle,  the  determination of  the  poten-
cy  for  one  valence  (type  A or C)  of bivalent or trivalent 
vaccines  can  be  carried out  in guinea pigs. 
To  this effect  56  guinea pigs,  weighing  about  450-550  g, 
should be  used.  28  of these  animals will be  given  subcu-
taneously  l/20th  of  the  usual  cattle dose.  28  animals  re-
main  untreated as  controls.  Challenge is carried out  18-21 
days  post vaccination.  Virus  strains,  designated by  the 
testing institute for cattle tests  to serve  as  infectious 
virus,  shall have  been  adapted  through  5-7  passages  in 
guinea  pigs  in such  a  way  that at least one  secondary 
vesicle  (generalization)  appears  after intraplantar in-
jection with o.5  ml  of  a  virus  suspension of  a  dilution 
of  10-2  in at least 90  percent of the  animals. 
Potency testing of the  vaccine is carried out by  titration 
of  the test virus  in both  the  controls  and  the  vaccinated ani-- 35-
mals.  Each  group  of  7  controls  animals is  infected by 
intraplantar injection with  0.5  ml  of virus dilutions 
-3  -6  from  10  to  10  •  Each  group of  7  vaccinated  animals 
receive  the  test virus  in  the  same  way  in dilutions 
~-,  -5 
ranging  from  10  ~  to  10  .  The  results  are  read  72  hours 
later and  an  animal  is  considered positive as  soon  as  a 
secondary vesicle is demonstrated.  The  titre calculation 
for  both  groups  is done  according  to the  method  of  Reed 
and  Munch.  The  protection  index  C  is  the  quotient of vi-
rus titre in  the  controls divided by  virus  titre in the  vaccina-
ted  animals.  The  protection index must  amount  to at least 
2.0,  in which  case  the titre in  the  controls  must  reach  at 
least  105  Io50/ml.  If the  titre lies below this  figure  the 
test can  be  repeated  in guinea pigs.  If, however,  the  pro-
tection  index  is  less  than  2.0,  the  potency test of  this 
valence  is to be  repeated  in cattle. 
Holland 
The  50%  protective dose  of  each  batch is measured  in guinea 
pigs.  A  mixture  of  each  four  of five  successive  batches  of 
one  type  is prepared  and  its Po50  is measured  in cattle. 
Three  four  fold dilutions  of  the  vaccine  in the  vaccine 
base  are  each  injected into five  steers.  These  are  then  chal-
lenged  by i.d.l. injections of  100.000 cattle  ID50  two 
weeks  after vaccination.  The  test is read  after  8  days 
when  the  animals  are  autopsied.  The  development  of feet 
lesions  is considered proof  of sufficient protection. 
It is desired  to have  10-12  cattle Po50  pro  type  into each 
dose  of vaccine,  the  minimum being  6  PD50• 
Italy 
Guinea  pig tests  and  seroneutralization tests  in cell 
cultures are  employed  for  in plant routine  controls  and 
also by Istitutc Superiore,  but the official tests are 
done  in cattle: 
The  trivalent vaccine is injected in  a  full dose,  and 
after dilution in buffer solution also  as  a  1/4  and 
1/16  dose.  Three  groups  of  15  animals  (15-24  months  old) 
are  injected and  in addition  three  animals  serve  as  con-
trols  in each  group. - 36-
Twenty  days  after  vaccination~ each  group of  18  anillals is 
challenged intradermolingually witn  10,000  ID50  of cattle 
virus distributed  over  two  different points  of  the  tongue. 
The  titration of  the  challenge virus  is  don~ in mice  and 
only  the  challeng2  dose  yroper  is  inoculated in  the cattle. 
The  a~imals are  observed  for  5  days:  one  single  lesion  in 
one  foot  means  generalization;  the  controls  must  genera-
lize within  48  to  72  hours.  Potency  is determined  quanti-
tatively by  the  Probits  method  (according  to Litchfield). 
Eight  Pb  (potenza bovina)  are  required against the 
homologous  virus.  Antibody  determination is carried out 
by  serum neutralization  (testing of pre-sera etc.)  ac-
cording to  a  standardized procedure. 
U.  K. 
Potency  is measured  by  the antigen extinction limit.  For 
this  purpose  the  final  product is diluted out  in  a  vac-
cine base  containing  the  normal  concentrations  of adju-
vants  (aluminium  hydroxide  and  saponin).  The  vaccine  is 
diluted out  in  5-fold steps  to give  the  series 1:2,  1:10 
and  1:50.  Groups  of  8  cattle similar to those  used  for 
innocuity tests  are  inoculated by  subcutaneous  injection 
behind  the  shoulder.  The  dose  volumes  are  3.0 ml  for  mo-
novalent  and  5.0 ml  for  trivalent vaccines.  Results  are 
calculated  from  either: 
(a)  Response  to challenge 
(b)  Assessment  of  each  animal's  neutralizing antibody 
titre. 
Challenge.  Cattle  are  challenged  at  21  days  after vacci-
nation  by  the  intradermal  inoculation of  the  tongue at 10 
sites with  104 ·0  cattle rn50  of  the  homologous  strain 
maintained  by serial passage  in cattle.  The  challenge 
strain is titrated by  the  intradermal  tongue  inoculation 
method  in  2  cattle shortly before  the  vaccinated cattle 
are  challenged.  These  cattle also  serve  as  controls  to - 37-
the  virulence  of  the strain and  must  show  the  rapid 
development  of severe  secondary  lesions.  Cattle  are 
classed  as  protected if no  secondary  lesions  develop 
on  the  feet.  The  test animals  are  observed  for  up  to 
10  days  after challenge. 
Antibody  essays.  All test cattle, whether  for  challenge 
or not,  are bled  for  serum before  vaccination  and  at  21 
days  after vaccination.  Neutralizing antibody titres of 
each  serum are measured,  using  the  Cell Metabolic  Inhi-
bition test  (CMI)  with  BHK  21  cells in microtrays.  For 
the  o1-BFS.l860  and  C-Noville  vaccine strains,  correla-
tions  of  antibody  levels  and  protection in  challenge 
tests  have  been  made.  With  the  type  0  vaccine,  cattle 
with  serum titres of  log10  1.65  or  higher  are  regarded 
as  "protected"  and,  with  the  type  C  vaccine,  the  appro-
priate figure  is  log10  1.20.  At  present,  vaccine:~  con-
taining  the  type  A  component  (A-Pando)  are  assessed by 
challenge  only  and  data  are being  accumulated  on  the 
correlation between  antibody  levels  and  response  to 
challenge. 
Calculation of results.  The  response  of test cattle to 
challenge  is assessed  on  a  quantal  response basis,  i.e. 
individual animals  are  classified as  protected or not 
protected and  no  attempt is made  at present to further 
quantify each  animal's  response  by  a  lesion scoring 
method. 
PD50  values  are  calculated by either the  method  of 
Spearman-Karber  or by full probit analyses.  The  minimum 
required standard  for  each  vaccine  or  component  of  a 
trivalent vaccine  is  6  PD50. 
3.  5.  4.  Expiration 
~lgium.  No  information  obtained. 
Denmark.  Retested every  6  months  if stored. 
France.  12  months  after the official taking of  samples. 
I'1ay  be  retested. - 38-
Germany.  18  months  after the official potency test. 
Holland.  18  months  after the  potency test.  Retesting 
is possible. 
Italy.  12  months  after the official potency test.  May 
be  retested. - 39-
3.  6.  V  a  c  c  i  n  a  t  i  on 
3.  6.  1.  Rules  for  Vaccination 
Belgium 
Vaccination is  compulsory  for all cattle older  than  3 
months.  The  vaccination  takes  plece  in  Dec.-March,  and 
not  more  than  13  months  may  pass  between  vaccinations 
(unless  the  vet.  inspeC'tor  has  decided otherwise). 
Denmark 
Danish  cattle is not ordinarily vaccinated,  but  the  Vet. 
Authorities  may  order vaccinations,  if considered  ne-
cessary in  connection with  acute  spread  of  disease  or 
may  permit  vaccinations,  if certain areas  or  groups  ap-
ply  for it. The  vaccination  may  only  be  carried ou·'- ac-
cording  to rules set by  the Ministry of Agriculture  and 
using  a  vaccine  furnished  by  the Vet.  Authorities,  who 
decide  which  types  of vaccine  should be  employed. 
France 
Vaccination  once  a  year  is  compulsory  for  cattle more 
than  6  months  old.  The  vaccination  must  be  carried out 
using  a  vaccine  tested  and  released by  the  control  lab. 
authorized by  the state. 
Germany 
Vaccination is  compulsory  once  a  year  for all cattle 
and  may  be  extended  to  sheep  and  goats.  (3.  Verordnung 
zum  Schutz  gegen die  MKS  §  1).  The  vaccination  must  be 
carried out  using  a  vaccine  made  and  tested  and  released 
according  to  the  "Anlage  uber  die  Impfstoffe"  attached  to 
the  regulation. 
Holland 
Each  animal  must  be  vaccinated once  a  year with  a  vac-
cine  licensed by  government.  The  vaccine  is delivered 
in  3  bottles a  5  ml.  The  vet.  officer is mixing  the  con-
tents prior to use. - 40-
Ireland 
In principle vaccination is forbidden.  As  the  country 
has  been  free  from  the disease,  no  license for  import 
of  vaccine  or its use  has  been  issued by  the  Department 
of  Health. 
Italy 
Annual  vaccinations  are  compulsory  for cattle,  buffalos, 
sheep and  goats  from  the  age  of  4  months  (except  for 
Valle d'Aosta)  according  to the  specified rules.  The  vac-
cine is prepared  according  to  the  suggestions  from  The  Mini-
stry of Publ.  Health  and  bought  solely by  the State.  A 
3-valent vaccine with  5  ml  total vaccine  dose  is employed. 
U.  K. 
The  use  of  FM  vaccine is forbidden.  At  the  Animal  Virus 
Res.  Inst.,  Pirbright,  a  stock of vaccine is held.  The 
only  licensed producer is situated at this institute, 
and  no  one  else is allowed to handle  the  virus.  The  vac-
cine has  never been  used. 
The  situation in the  different Member  States is  summarized 
in Table  1. 
3.  6.  2.  Economics 
The  rules  for  payments for vaccines  and  vaccinations differ 
from  one  Member  State to the other.  It varies  also ac-
cording to the  type  of vaccination,  i.e. if it is  compul-
sory,  encouraged  or permitted. 
The  information obtained is as  follows: 
Belgium 
No  information obtained. 
Denmark 
Both  the  vaccine  and  the  vaccination are  payed  for by  the 
State  when  vaccination is required. - A40-
Table  2.  Foot- and  Mouth  Disease  Vaccine  in Cattle 









U.  K. 
Vaccination  paid by 
The  State 
The  farmer.  In  some 
parts  of  France  paid 
by  local authorities 
In part by  the State 
in part by  an  epide-
mic  diseases  fund  to 
which  every  farmer 
contribute 
The  farmer 
The  State 
Indemnities  in case  of  vaccine-
associated  accidents  paid by 
The  situation has  not  occurre~, 
and  no  rules  are  fixed 
The  State in cases  of  death  in 
immediate  connection with  the 
vaccine 
In principle the State 
The  epidemic  diseases  fund 
paid by  the  farmers 
The  producer  (the  State} 
Officially the State,  but in 
fact  the  producing institute - 41-
France 
The  farmers  pay  in general for  the  vaccine  and  vaccination, 
but in  some  provinces it is paid for  through  the  local  autho~ 
rities. 
Germany 
The  vaccinatio~ is in part paid·for by  the State  and  in ~art 
by  a  vaccination-fund,  to which  the  farmers  contribute 
according  to  the  number  of animals. 
Holland 
The  farmer  must  pay. 
Ireland 
No  vaccination. 
Italy 
The  vaccination is paid for  by  the State. 
U.K. 
No  vaccination. 
The  material of  3.  6.  2.  is collected in Table  2. 
3.  6.  3.  Indemnities 
In  case  of vaccine-associated accidents  the  economic 
responsability is in  some  Member  States defined clearly 
and  in other  cases  apparently not at all. 
The  information obtained  is  as  follows: 
Belgium 
The  situation has  not occurred,  and  no  rules  are  fixed. 
Denmark 
The  State pa7s  indemnities,  if death  occurs  in 'imme-
diate  connection with  the  vaccination. - 42-
France 
In principle  indemnities  are  paid  by  the State. 
Germany 
Indenu1i ties  arE:  paid  by  the  vaccination-fund,  to which 
the  farmers  contribute according  to  the  number  of  animals. 
Holland 
The  State  (the  producer)  pays  indemnities. 
Ireland 
Vaccine  has  never  been  used  in Ireland. 
Italy 
Officially it is  the State authorities 1  but  in fact  it is 
the  producing institute.  The  Brescia Institute has  u  spe-
cial voluntary  insurance,  that will cover  immediate  deaths 
in connection with  vaccinations.  The  insurance  has  seldom 
been  used. 
U.  K. 
The  vaccine  has  never  been  used  in U.  K. 
The  rules  are  summarized  in Table  2. - 43-
3.  7.  Propos a  1  s  for  Communi t  y 
R  e  g  u  1  a  t  i  o  n  s 
3.  7.  1.  A  Summing  up  of  the  pte~:;ent Situation 
The  Council  Directive of  26  June  1964  (64/432/EEC)  and 
the  amendments  following  (66/600,  70/360,  71/285  and 
72/97)  state,  that measures  must  be  taken  to eliminate 
differences  between  the health requirements  of  Member 
States. 
There  are still possibilities for  nationally maintaining 
severe restrictions  on  imports  and  exports  or transits 
in order  to safeguard  the health  of  man  and  animals  in 
acute  defined situations 1  but  such  possible rights  do 
not  suppress  the  duty  of  providing conditions  that 
may  result in the  realisation of  a  mutual  Community  policy. 
It is also clearly stated,  that it is the  duty  of  the 
individual Member  State to guarantee,  that animals  for 
breeding or slaughter do  not constitute  a  risk  of  spreading 
infection  thr0u~b intra-community activity. 
The  present  day  situation of F.M.D.  vaccinations within 
the  Community  is quite  complicated  (see e.g.  table  1  and 
2).  Vaccinations  are  compulsory  in  6  Member  States  and 
not  employed  in the  three  new  Men~er States, but within 
the  6  states there  are  important differences  in  the  ru-
les  for  production  and  control.  European  Pharmacopoeia 
Commission  rules  for  vaccine  production  and  standards 
are  apparently  not  finalized.  According  to the  European 
Treaty Series  No.  50,  the  rules  agreed  upon  by  the  Phar-
macopoeia  Commission  should be  the official standards 
for  the  member  countries,  so it is of  obvious  importance 
not  to  make  any  suggestions within  the  Community,  which 
arein disagreement with  the  decisions  of  the  Pharmaco-
poeia  Commission. - 44-
3.  7.  2.  Proposal  for  a  Community  Regulation 
In  view  of the  general  duty  according to the  Rome  treaty 
the  following  proposal  is suggested: 
l)  As  a  common  rule  for  the  Community,  vaccination of 
all cattle should be  compulsory  once  a  year  employing 
an  inactivated vaccine  of  agreed European  standard. 
2)  If a  region  has  previously been  maintained  unvacci-
nated,  and  no  cases  of  FMD  are  diagnosed  in the  area, 
such  region  may  be  maintained without  vaccination.  Con-
sequently  only  live cattle exported to vaccination-re-
gions  must  be  vaccinated.  It may  be  decided by  Permanent 
Veterinary  Committee  ruling to  extend the  non-vaccination 
areas  beyond  the existing ones.  The  right to maintain 
an  area without vaccination  does  not  give  the  right to 
prevent  import to such  areas  of vaccinated  live animals 
or of meat  from  vaccinated animals. 
In  connection with this proposal it might  be  reconsidered, 
whether vaccination  for  transfer to vaccinated  areas  is 
in  fact reasonable.  Such  vaccination was  originally in-
troduced to protect the  importing country,  but if the 
level of protection is sufficiently high  through  vaccina-
tion of  a  high  percentage of  animals  the  introduction of 
a  limited number  of  unvaccinated  animals  may  not  change 
the  epidemiological situation very  much,  if at all,  and 
newly  vaccinated animals  may,  in rare  instances,  intro-
duce  a  risk of spreading the  infection. 
3.  7.  3.  Licenses  for Vaccine  Production 
3.  7.  3.  1.  Present Situation 
There  are  two  kinds  of licenses:  l)  Establishment Licenses 
and  2)  Product Licenses. 
Both  for  the  establishment  licenses  and  the product li-
censes  the rules differ significantly between  the  Member 
States.  In  Belgium,  Denmark  and Holland  a  specific State 
Institute produces,  and  the  same  institute controls  the 
vaccine.  In Italy four State Institutes produce,  whereas 
separate institutions control  the  product.  In France,  Ger-
many  and  U.K.  licensed private  firms  produce,  and  a  speci-- 45-
fie State Institute controls  .  In  Germany  the  right  to 
issue establishment  license lies within  the  regional 
(Lander)  authorities,  but  in France it lies with  the 
State. 
3.  7.  3.  2.  Proposal  for  a  Community  License 
The  goal  of obtaining harmonization  also  in vaccine  pro-
duction  might  be  reached  through  Community  Licenses  va-
lid for all Member  States.  In order to obtain this  the 
Community  as  well  as  the Nat.  Auth.  would  have  to 
establish regulations,  which  deal with  other  areas  than 
just the  vaccine  standards which  are  treated by  the 
European  Pharmacopoiea  Commission. 
Proposal: 
1)  Establishment  licenses shall be  issued only  after 
inspection  resulting in  a  determination  that the 
establishment complies  with prescribed standards. 
2)  A  product  licen~e shall be  issued only  upon  examina-
tion of the  vaccine  and  provided that the  vaccine 
complies with  the  standards  prescribed  and  that the 
establishment is accepted. 
The  details  regarding  License  Forms  etc could be 
worked  out  in  such  a  way  that the  result could be 
a  common  Community  License  valid for all Member 
States.  The  norms  are  to be  worked  out by  Permanent 
Veterinary  Community  procedures. 
3.  7.  4.  Standardization of Vaccine 
l)  Reference  Lab.  If  a  Community  License  is  attempted 
and  even if National  License must still be  obtained di-
rectly in the  individual  Member  State, it is essential, 
that  a  reference  laboratory be  established.  Such  a  labo-
ratory  could work  together with  the  National  Lab.  in  a 
trial period  (probably  not  more  than  3  years)  with  pro-
visional rules.  It may  be  sufficient just to  formalize 
the existing collaboration,  but  the  Reference  Laboratory 
must  be  totally independent of production.  After this 
period and  after adjustment  of the  rules  a  free  trade  for 
vaccines  could be  established. - ~6-
Proposal: 
The  reference  lab.  should provide  information  and  re-
commendations,  e.g.  on  methods  and  on  new  virus  strains 
appearing  in  the  Member  States or in countries exporting 
to  the  Member  States.  It should provide  seed lot virus 
to be  used  as  challeng~ in  the  potency tests or make  de-
cisions  on  the  use  of special strains  in special situa-
tions. 
The  Nat.  Labs.  must  collaborate with  this  Ref.  Lab.  and 
mutual  decisions  must  be  followed  by  the  Nat.  Labs. 
2)  Control  of production  and  issuing of licenses. 
The  establishment  licenses  and  the  production licenses 
are  issued by  the Nat.  State Lab.  or Nat.  Authority 
authorized to  do  so.  The  work  should be  carried out  ac-
cording to  Community  Regulation.  By  the  Community  Regula-
tions it should be  stated also,  if production controls 
could be  carried out  by  repressive control  and  the  types 
of  tests carried out. 
The  Community  regulation should be  in  an  agreement with 
the  Pharmacopoeia  rules  for  storage:  The  vaccine  should 
0  be  kept  at  2-6  C  and  should not  be  allowed  to  freeze.  The 
expiration date  should be  12  months  calculated  from  the 
day  on  which  the official test for  potency  is  begun~ 
Norms  for  labeling etc  should  follow  the  Pharmacopoiea 
rules  and  be  worked  out by  Permanent Veterinary  Committee 
procedures.  In  addition  to  the  Pharmacopoiea  rules  the 
label  should state the  method of cultivation of  the  virus 
preparation. 
3.  7.  5.  Minimal  requirements  for  FMD  vaccines  for cattle 
3.  7.  5.  1.  Background  papers 
As  it seems  that the  German  comments  of  1  Aug.  1973  to 
PA/PH/Exp.  15V/T  (70)12,  4th  rev)  have  influenced the 
document  of  20  March,  1975  (French)  marked  PA/PH/Exp. 
15V/T  (75)2,  this  later document  is supposedly  at the  mo-
ment  the  nearest  approach  to  a  final  decision of  the 
Pharm.  Corn .. It is  consequently  the  base  of  the  following 
proposal.  It has  been  compared  also with  the  re-- -l7-
port of the  European  Commission  for  the Control of  FMD 
from  Lelystat  22-24  October  1974.  In the  Recommendations 
of  the  XIII  Conf.  of  the Permanent  Commission of  the  OIE 
(1972),  which is completed  in the document  from  the  XIV 
Con£.  of  1975,  it is stated,  Point  5  about potency testing, 
that it should  be carried out  in cattle,  and  that the 
potency  for  each virus  type  should  be  expressed  in mini-
mum  protective doses  in completely receptive cattle. 
One  dose of vaccine  should contain as  a  minimum  a  dose 
sufficient for  the  immediate protection of  70  per cent 
of the vaccinated animals. 
Other methods  may  be  applied as  supplementary methods  in 
the potency testing,  if a  correlation has  been  established 
between  the method  in question and  the evaluation of pro-
tective doses  in cattle,  Po50 •  "The  likely performance 
in the  field,  which is influenced  by  many  factors,  can 
be  left to  the user,  who  is aware  of  any  special  local 
condition"  (p  11  of the report  from  the  European  Comm. 
for  the Contr.  FMD,  1974). 
3.  7.  5.  2.  Proposal  for  minimal  requirements 
The  proposal  for  the minimal  requirements of  an  inac-
tivated  FMD  vaccine  for cattle  (in accordance with  the 
available documents  and  with the principle guide-line 
of  following  the  European  Pharmacopoeia  Comm.  decisions, 
when  available)  would  be  as  follows: 
Inactivated  FMD  vaccine is a  liquid preparation con-
taining one  or more  types or  sub-types of  foot-and-
mouth disease virus which  have  been  inactivated in such 
a  manner  that their antigenic activity is retained. 
Preparation 
The  vaccine is prepared  by  propagating  the virus either 
in susceptible animals  which  have  not  been vaccinated,  or 
in suspensions of bovine  tongue  epithelium taken  immediate-
ly after slaughter  from  animals  free  from  foot-and-mouth - 48-
disease,  or  or.  cell cultures.  Tb.e  virus  is  removed  from 
the  cellular material  and  inactivated under  appropriate 
conditions  by  a  suitable  agent.  The  vaccine  may  be  con-
centrated and  purified.  One  or more  adjuvants  may  be  added. 
l;:dentif  ig_atioJl. 
The  serum of  an  animal  injected with  the  vaccine  must 
neutralize  the  types  or sub-types  of  the  virus  used  for 
preparing  the  vaccine  in  a  proper test. 
s t&.!j.jj._ty_. 
The  vaccine  complies  with  the  test for sterility of  the 
Ph  arm.  Conun .. 
Innoc.ui  t_y  tests  . 
The  tests  for  innocuity  are  carried out  in  two  ways  and 
for  a  vaccine  to be  acceptable both  tests must  give  sa-
tisfactory results .. 
1.  Tests  in cell cult4res after elution-concentration. 
A  sample  of  3  1  of vaccine  is centrifuged.  From  the  sedi-
ment  virus  is eluted  and  concentrated  to  1/60 of  the 
original  volume.  The  concentrate is  inoculated in cell 
cultures  sensitive to  FMD  virus~  preferably of  the  same 
type  which  h&e been  employed  for  the  preparation of  the 
vaccine.  The  cultures  are  observed  during  a  3  day  period. 
Two  passages  into  new  cultures  are  carried out  in  the 
same  way.  No  cytopathic effect caused by  FMD  virus  may 
be  observed. 
2.  Test in cattle.  Carry  out  the  inoculation by  the 
intradermolingual route  using  0~1 ml  of  the  vaccine  at 
each site.  Observe  the  animal  for  at least ten  days.  The 
animals  should then  be  killed and  no l~ions of  foot-and-
mouth  disease  should be  observed at autopsy. 
Poten£Y_~~-
The  potency  of  a  vaccine  should be  expressed  as  the  per-
centage  of protection of  primary  vaccinated cattle.  A 
vaccine satisfies  the  minimal  requirements,  if it pro-
tects at least 70  per cent  (confidence  limit  P  = 0,95) - 49-
of  the  animals  challenged with  10.000 bovine  rn
50 
of 
the  same  sub.Lypes  as  employed  in  the  vaccine  preparation. 
For  the  tests  18  to  30  months  old  animals  obtained  from 
areas  free  fr0m  FMD,  which  have  not previously  been  vacci-
nated  against  FMD  and  are  free  from  neutralizing anti-
bodies  against FMD.  The  animals  are  vaccinated with  the 
dose  indicatej on  the  label,and the  challenge is carried 
out  3  weeks  after  the  vaccination.  The  challenge  is  car-
ried  out  by  i~tradermal injection into  the  upper  surface 
of  the  tongue  of 0.1  ml  in  each  of  two  sites of  10,000 
bovine  rn50 .  The  test is  carried out separately  for  each 
type  of  virus.  Control  animals  will  have  lesions  on  at 
least three  feet.  Protected animals  may  display  lingual 
lesions,  but  only  unprotected  animals  show  lesions  at 
sites other  than  the  tongue.  The  animals  are 
observed  for  10  days  and  slaughtered. 
Several different methods  may  be  employed  for  the  quan-
titative evaluation in cattle of  the  potency  provided l)that 
the  method  is widely  known  and  2 )  that it is shown,  that 
there  is  a  satisfactory statistical correlation between  the 
results  obtained  and  the  prescribed degree  of protection. 
Thus  e.g.  an  estimation of  PD50  could  be  applied.  Here it 
seems  advisable  to calculate on  the  base  of  dilutions  made 
without  the  addition of adjuvants,  because  of  the better 
precision in  the  titrations.  If adjuvants  are  employed  a 
correlation factor  should be  known  for  the  type  of  vac-
cine  in question. 
Another  way  of estimating the  potency would  be  through 
establishing the  K-value  of  the  vaccine,  i.e.  the  index 
between  the  titre of virus  obtained  jn  unvaccinated cattle 
and  in vaccinated cattle. 
3.  7.  6.  Vaccination  Programmes 
Although  identical vaccination  programmes  should  in prin-
ciple be  applied  in all the  Hember  States  the  actual  local 
conditions  may  make  deviations  permissible. -50-
The  vaccinations  should  be  carried out  once  a  year. 
Young  animals  should be  revaccinated.  In  cases  where 
the  vaccination  programmes  are  not sufficiently syncro-
nized  an  additional  vaccination  could be  required  for 
intra-corr~unity trade. 
The  animals  should  be  vaccinated  according_to what  is 
prescribeQ_ey_!he_producer,  but must  be  carried out by 
ubcutaneous  inoculation in  the  dewlap. -51-
3.  8.  F  M  D  v  a  c  c  i  n  a  t  i  o  n  o  f  p  i  g  s 
The  European  FMD  situation in  number of countries until 
around  1960  was  an  enzootic  one with  infections  in 
cattle amounting  to  15-20 per cent at the peaks  of epi-
zootics.  In  a  single  unvaccinated herd the percentage 
of  infected animals  might  reach  90-100.  Usually  the  mor-
tality remained  low.  After  compulsory  vaccinations  com-
bined with  eradication programmes  the  situation changed 
drastically  and  FMD  disappeared  almost  completely  in 
cattle. 
In  sheep,  goats  and  pigs  the  morbidity was  apparently 
very  variable  in the period before  compulsory  vaccina-
tions,  and it was  considered to be  inferior to  the  mor-
bidity  among  cattle.  As  the  clinical diagnosis  in other 
animals  e.g.  pigs  is more  difficult than  in cattle, it 
seems  now  possible,  that the  real difference is not  as 
important  as  hitherto accepted.  Whatever  the  explanation 
it is  now  apparent that severe  epizootics  among  pigs  may 
start in areas with  high densities of pigs.  This  has 
happened  in Holland  in  1965-66  and  in France  in  1974.  In 
this  connection it has  been  pointed out,  that even with 
a  successful,  compulsory  prophylatic vaccination of cattle 
the  young  calves,  the  sheep,  the  goats  and especially the 
pigs  may  easily be  in  such  proportion,  that in fact  less 
than  50  per cent of the  animals  sensible to  FMD  are ac-
tually vaccinated.  Thus  an  epizootic  among  unvaccinated 
animals  may  easily occur,  especially if the  vaccinated 
animals,  due  to high  densities of pigs,  are  even  less 
than  25  per cent of all the  sensible animals. 
Although  prophylactic vaccination of pigs  is not  sugge-
sted,  it has  been  shown,  that vaccination  may  limit epi-
zootics  in pigs.  It is suggested,  that the  vaccines  em-
ployed  should contain  8  times  the  dose  employed  for cattle. 
According  to French  results  revaccinations with  a  stock-
virus  already  employed  may  be  useful  and provide partial -52-
protection and  stop an  epizootic for sufficiently long at 
least to give  time  to prepare  a  homoloqo~s vaccine.  In 
animals  not  va.ccina ted before,  it requires the homologous 
vaccine  to give  protection. -53-
4.  SWINE  FEVER  VACCINE 
4.  1.  I  n  trod u  c  t  i  on 
A  common  policy  of controlling classical swine  fever  does 
not exist, not  even  within the  Member  States,  and  a  number 
of  questions  concerning  the  virus  and  the disease  are 
still unsolved.  Thus  questions  about  factors  important  for 
the  occurrence  of  latent infections  in pigs  and  the rela-
tionship between  bovine  virus-diarrhoea mucosal  disease 
virus  are still partly  unknown  or  open  for  discussions. 
In  addition  to  problems  concerning  the  interrelationship 
between mucosal  disease  virus  and  classical swine  fever 
virus  the  possible relationship between  the  virus  causing 
IDrder  disease  in  :heep  and  the  virus  of  cattle and  pigs 
is also of potential interest in  a  vaccination  programme 
designed  for  the  control  of  classical  swine  fever. 
4.  1.  1.  Classical  Swine  Fever  Virus 
Although  not yet officially classified as  a  togavirus 
the  classical Swine  fever  virus  (SFV)  is at least accep-
ted  as  related to the alfavirus  group  of togaviruses. 
The  alfavirus  group  contains  the  "old"  arboviruses  of 
the  A.  type.  In addition  to  the  swine  fever virus,  it 
seems  possible to  include  in  the  same  group  not  only 
the  closely related mucosal  disease  virus  (virus  diarrhoea 
virus)  of cattle,  but  also  the  human  rubella virus  and 
the  equine arteritis virus.  The  virus  consis~of a 
RNA  Strand enclosed in  a  protein shell of  icosahedron 
symmetry.  The  outer layer is  an  envelope,  and  the whole 
particle has  a  diameter of  around  40  nm.  The  virus  mul-
tiplies  in pig cell cultures,  but  does  not  usually  give 
cytopathic  changes  of the cells.  The  laboratory  diagno-
sis has  been quite difficult,  but special methods  have 
been  developed.  Minor  antigenic differences between  SFV 
strains exist. 
The  virus  seems  qui·te  resistent towards  drying at  room 
temperature,  and it takes  extreme  values  of  pH  to  cause -54-
rapid inactivation  (pH<. 1. 4  or  pH  >  13) .  The  virus  may  per-
sist a  long  time  in pork  and  garbage.  The  virus  may  pas-
sively be  transfered by  contaminated persons. 
Although  the  disease African  swine  fever  (ASF)  in  an  indi-
vidual  case  may  be  clinically very difficult to distinguish 
from  classical  swine  fever,  the  ethiological  agent  of ASF 
is  a  quite different virus.  The  ASF  virus  is  a  DNA  virus  of 
the  iridovirus  group,  which  consists of  large  (around  200  nm 
diam.)  naked  icosahedrons.  The  ASF  virus  is also  immunologi-
cally quite distinct  from  the  virus  of classical  swine  fever. 
The  ASF  virus  may  survive  for  years  when  dried at  room  tempe-
rature. 
The  Cornm.  of The  European  Communities  has  published  a  study 
(October  1971)  on  "Properties of the  virus  of classical  Swine 
fever  and differential diagnosis  of classical  and  African 
swine  fever"  containing  a  wealth of  information. 
4.  1.  2.  Classical Swine  Fever 
Synonyms:  Hog  cholera,  European  swine  fever. 
The  infection is  us~ally exceedingly  contagious  and  may  be 
fatal.  Some  strains of  low  virulence  are  not  very  contagious 
and it can  take  many  months  to infect  a  whole  herd with  such 
strains.  Only  pigs  are naturally infected.  The  infected ani-
mals  may  have  fever,  apathy,  vomiting,  eye-discharge,  diar-
rhoea,  haemorrhages.  Some  strains are mild,  but others  may 
be  unusually  neurotropic with  frequent  symptoms  of  ence-
phalomyelitis.  Even with  attenuated virus  strains trans-
placental  infection  may  give still-births or diseased newborns. 
In  the  case  of virulent virus  strains transplacental  infec-
tion becomes  unimportant because  of  the high  mortality  of the 
infection in the  sows. 
The  infection may  spread by  direct contact  and  by  feeding 
contaminated  garbage.  Only  pigs  are naturally infected. 
4.  1.  3.  Control 
As  hyperirnrnune  sera  may  give  temporary protection simul-
taneous  inoculation of virulent virus  and  intisera has  been 
employed,  but this method  may  lead  to persistent infec-
tions  and  has  been  abandonned. 
Virus  inactivated by  crystal violet has  been  employed, -55-
but only  temporary  immunity  is obtained in this way.  Live 
attenuated vaccines  are  now  being employed.  They  are at-
tenuated by  passages  in rabbits  or  in cell cultures. 
The  problems  encountered with  these  vaccines  are,  that 
the  vaccine virus  sometimes  may  cause  abortions  or mal-
formations  amongst  litters when  pregnant  sows  are vacci-
nated.  Some  workers  suggest that  so~e vaccine virus strains 
may  sensitize pigs,  so  that they  react with  more  severe 
symptoms  than otherwise  in  case of  a  challenge  through 
natural infection later on. 
Control  of African  swine  fever  by  vaccination is especial-
ly difficult because  many  different serotypes of the vi-
rus  exist.  Attempts  have  been  made  to  use  attenuated strains 
as  vaccines,  but vaccinated pigs  may  continue to carry the 
virus. 
Both  in classical swine  fever  and  in African swine  fever 
the  vaccinated animals  may  become  carriers,  perhaps  even 
persistent carriers of virus.  Thus  it is once  more  stres-
sed,  that the  goal  must  remain  an  eradication programme, 
as  the  only  real control  in the  long run.  In all cases, 
where  such  a  programme  is not  feasible,  the  vaccination 
programmes  must  be  full scale vaccination. -56-
4 .  2.  L  e  g  i  s  1  a  t  i  0  n  a  n  d  r  e  g  u  1  a  t  i  0  n 
f  0  r  v  a  c  c  i  n  e  s  a  g  a  i  n  s  t  c  1  a  s  s  i-
c  a  1  s  vl  i  n  e  f  e  v  e  r  i  n  t  h  e  d  i  f  f  e-
r  e  n  t  M  e  m  b  e  r  s  t  a  t  e  s.  A  r  e  v  i  e  w 
0  f  X'  e  1  e  v  a  n  t  d  0  c  u  m  e  n  t  s. 
Belgium 
...... 
Arret~ royal  du  18  juin  1968  portant des  mesures  de  po-
lice sanitaire relatives  A  la peste porcine  {in:  Bull. 
Sanitaire No.  13  (1968)  p.  132-168),  which  contains de-
tailed descriptions  of  the practical control,  slaughter, 
indemnities  quarantaine etc.). 
/". 
Arrete ministeriel du  1.  oct.  1969  portant des  mesures 
de  police sanitaire relatives  ~ la peste  porcine  {in 
Bull.  Sanitaire No.  1~  {1969)  p.  276-278),  which  state 
that only  vaccine  of  the  Chinese  strain or equivalents 
controled by  the  Nat.  Institute  and  that the  use  of anti-
serum is prohibited etc. 
A. 
Arrete royal  du  28  octobre  1969  modifiant  l'arrete du 
18  juin  1969  {must  be  a  printing error for  1968)  {in 
Bull.  Sanitaire No.  21  (1969)  p.  308-310),  about  indem-
nities. 
Arrete ministeriel du  25  mai  1970 portant des  mesures  de 
police sanitaire relatives  A la peste porcine  {in  Bull. 
Sanitaire No.  12  {1970)  p.  200-204,  containing  among  other 
things  the  rules  for  the  compulsory  vaccination of cer-
tain categories  of  pigs. 
Ar~te royal  du  18  juillet 1972,  rnodifiant  l'arr~te royal 
du  18  juin 1968,  portant des  rnesures  de  police sanitaire 
relatives  A la peste  porcine  (in  Bull.  Sanitaire No.  17 
(1972)  p.  176-182)  containing certain changes  in rules 
for  indemnities,  protective  zones  etc. 
~  A 
Arrete rninisteriel du  7  decembre  1973,  rnodifiant  l'arret~ 
rninisteriel du  25  rnai  1970 portant les mesures  de  police 
sanitaire relatives  A la peste porcine  {in Bull.  Sanitaire 
No.  3  (1974)  p.  24-26~  in which  minor  changes  in the pre-
vious  administrative rules  are  introduced. -57-
Denmark 
Apotekerloven  af Juli  1962  (Drug  act). 
Landbrugsministeriets  bekendtg¢relse  om  ondartede  smit-
somme  sygdomme.  has  svin  (J-uni  197 3).  (Order  by  the Mini-
stry of Agriculture  on notifiable  communicable  diseases  of 
swine.) 
France 
Legislation  Le  code  de  la Sante  Publ.,  Articles  L  611  A 
L  617. 
In  addition  the ministry has  issued provisional regulations 
for  the  special vaccines  until agreements  have  been  reached 
by  the  European  Pharmacopoeia  Commission.  The  Pharmacopoeia 
rules will  then  be  employed. 
Germany 
Verordnung  uber  Sera  und  Impfstoffe  nach  §  17c  des  Vieh-
seuchengesetzes  (Febr.  1973). 
Ausfuhrungshinweise  zur  Verordnung  iiber  Sera  und  Irnpf-
stoffe nach  §  17c  des  Viehseuchengesetzes  (Marz  1973). 
No  special  regulations  for  swine  fever  exist. 
Holland 
No  special  legislation. 
Ireland 
No  special  legislation. 
Italy 
La  legge  7  luglio 1967,  n  514  according  to which  the mini-
stry may  order  compulsory  vaccination. 
Ordinanza Ministeriale  11  Agosto  1967:  Vaccinazione  obli-
gatoria dei  suini  contra  la peste suina classica  (G.U. 
25-8-1967),  according  to which  vaccinations  are  compulsory -58-
employing  a  vaccine  of the  Chinese  strain.  The  order 
contains  further details about  the  vaccination. 
Circolare del Ministero della SanitA.  Direzione  Gene-
rale dei Servizi Veterinari nr.  600.5/24486/AG.2494 
in which  the  testing of vaccine is described. 
U.K. 
The  Medicines  Act.  1968  and  1971. 
Regulations  can be  laid down  for  individual vaccines, 
but have  not been  for  swine  fever vaccine. -59-
4.  3.  P  r  o  d  u  c  t  i  o  n 
4.  3.  1.  Identification of  the  Producer 
Belgi  un~ 
Different private  firms  if licenses  for  release  are  ob-
tained  from  the  Institut Nat.  Recherches  V~t. 
Denmark 
No  Danish  production,  Imports  only  by  permission  from  the 
Ministry of  Agriculture. 
France 
Vaccines  are  produced  by  firms  who  have  obtained authoriza-
tion after the  required tests. 
According  to Direction des  Services Vet.,  Ministere  de 
!'Agriculture, all biologicals  for  veterinary  use  produced 
or  imported  must  be  authorized  by  the  ministry.  Then  a 
license  may  be  obtained  for  5  years.  Prior  to  a 1lthoriza-
tion or  renewal  of this  the  product  may  be  tested by  a 
State control  laboratory. 
Germany 
Vaccines  may  be  produced by  firms  authorized  to  do  so  by 
Bundesforschungsanstalt der Viruskrankheiten  der Tiere, 
Tubingen. 
Holland 
In Holland  a  private  firm  (Philips)  has  a  special  authori-
zation to produce,  but  imports  are  permitted also. 
Ireland 
No  production. -60-
Italy 
Vaccines  produced by  institutes  licensed to do  so  by 
the State.  Production is made  according  to direction 
by  the Ministry.  (There  are  now  the Ist.  Zooprofylat. 
in Termo,  Perugia  and  Bresci~. 
U.K. 
No  U.K.  production is permitted.  The  vaccines  are  imported 
if wanted  for  exports  of  pigs. 
In  table  3  the material  of  4.  3.  1.  is compiled. 
4.  3.  2.  Licenses  for  Establishment 
Little information  on  special requirements  for establish-
ment  licenses has  been  found  for  the different Member 
States,  where  production  is permitted at all. 
4.  3.  3.  License$  for  Release 
Belgium 
Only  vaccines  prepared employing  the  Chinese  strain and 
controled and  released by Institut Nat.  de  Recherches  V~t., 
or  other vaccines  accepted by  the  institute as  equally 
good,  may  be  used. 
The  license  for  vaccines  depends  on  fulfillment of  the 
following criteria: 
General  standards  for  attenuated live vaccines: 
l)  A  proper degree  of  attenuation. 
the  vaccine  must  be  harmless  for  use without  simultaneous  use 
of antisera  (the  use  of  antisera is  forbidden  anyway)  and 
without  any  special precautions  or  mode  of  application. 
2)  The  vaccine  must  pass  the required tests  for  innocui-
ty and  potency  in  immunosuppressed  (Prednisolone)  and 
normal  piglets by vaccination  and  challenge  according  to 
specified rules. 
3)  Innocuity  for  embryos  and  fetuses  is tested. 
4 >  Resistance  against contact infection must  be  proven - 61-
for  vaccinated  pigs  (test method  specified). 
S)  Stability of  the  attenuation must  be  proven  (6  p0rcine 
passages  shoul~ be  made,  and  the  last passage  should not 
cause  symp-toms  of  infection, but  should give  a  vaccination, 
which  must  be  challenged). 
6 )  An  immunity  of at least  3  months'  duration  must  be 
obtained by  the  vaccination. 
7 )  Immunofluorescense  tests should  be  negative. 
Only  the institut Nat.  Recherches  Vet.  may  release  vac-
cines.  The  distribution is  through Vet.  Authorities. 
Denmark 
Imports  only by permission  from  the Ministry of Agriculture. 
France 
The  release is given by  the State laboratory.  The  authori-
zed  vaccines  must  be  prepared  according  to specification 
regarding  ider1tification of  the  virus  strain,the method 
of preparation,  passage,  quality etc,  required by  the  Mi-
nistry of Agri.cul ture. 
Germany 
Bundesforschungsanstalt der Viruskrankheiten der Tiere 
would  be  the ,controling  and  releasing institute,  but  the 
vaccine  is not  employed  in Germany,  and  no  specific rules 
exist for  Germany. 
Holland 
The  Vet.  Authorities  follow  the  system of  preventive  con-
trol.  When  a  batch is produced,the  producer  applies  to VD, 
who  collects  samples,  which  are  sent to CDI.  The  VD  can 
then  release  the batch before test results.  Imported vac-
cines  are  sampled  "at the  border".  Responsibility is al-
ways  with  the  producer  in Holland. 
Ireland 
The  vaccine  is  in principle  forbidden.  Import would  be - 62-
for  emergencies  by  permission of  the  Department  of 
Health  (after consultation with  the  Department  of 
Agriculture),  but  a  license has  never been  issued. 
Italy 
All  vaccine batches  are controled by  Istituto Supe-
riore di Sanita and  released by  the Ministry. 
U.K. 
Vet.  Authorities  may  permit  import of vaccines  for 
use  only  for  exported pigs. - 63-
4.  4.  C  o  n  t  r  o  l  i  n  g  Au  t  h  or i  t  i  e  s 
In all countries  where  the  vaccines  are  produced at 
all the  State in principle  controls  the  vaccines.  In 
some  cases  the  control is actually carried out  and  in 
other countries  like Holland  the  samples  are  taken 
f  o  r  o  o  n  t  r  o  1.  In France  the  samples  for  control 
are  not  taken  systematically 1  but  the  producer must  ful-
fill the  specified requirements  and at the  time  of 
establishment  license  the  seed  lots  are  examined  for  to-
xic effects,  teratogenicity,  innocuity,  potency,  spread 
of  virus  etc. - 64-
4.  5.  T  h  e  C  o  n  t  r  o  1  s  a  n  d  S  t  a  n  d  a  r  d  s 
r  e  q  u  i  r  e  d 
4.  5.  1.  General  Rules 
Belgium 
Immunofluorescense  tests must  be  negative.  For Belgian 
products  the  potency test may  be  restricted to every 
fourth  lot,  but  serum neutralization  for  identification 
must  be  done  on  each  lot,  and  innocuity test must  be  car-
ried out  for all vaccines  and  for  each  lot employing pig-
lets.  The  stability of  the  vaccine  is controled by  expo-
sure  to  37°C  for  7  days  followed  by  control  inoculations 
in rabbits. 
Denmark 
The  controls  and  standards  that might  be  required in  case 
of  imports  are  not  specified. 
France 
Although  there is  no  legislation the authorities  have 
specified requirements  pending  the  Pharmacopoeia  Commis-
sion decisions. 
It is stated that the  live vaccine  is a  product  containing 
a  strain of classical swine  fever  virus,  which  has  lost 
its pathogenicity  for  pigs  through  adaption  in  rabbits. 
It is  identified by  serum neutralization tests in rabbits, 
where  the  fever  provoked  by  intravenous  injection of the 
virus  is  employed  as  the clinical sign of  infection. 
There  are detailed rules  for  the origin of the  seed virus. 
The  vaccine  may  only  be within  5  passages  of the  seed vi-
rus.  After sterility tests  and tests  for toxicity  and  te-
ratogenity,  the possible spread of virus  must  be  examined. 
Five  days  after vaccination the  animals  must  be  protected 
(the  definition of protection being  that the  animals  sur-
vive without  a  temperature  rise to  41.5°C  for  more  than 
24  hours) . 
On  the  vaccine  label  should be  stated,  that the  reconsti-
tuted vaccine  must  be  employed  immediately,  and that it - 65-
is not  recon@ended  for  pregnant  sows. 
Germany 
No  specific rules exist,  only  the  general  legislation 
for  vaccines. 
Holland 
Requirements  for  vaccine  standards  and  control methods 
are  not  finally settled.  The  Pharmacopoeia discussions 
are  closely  followed.  Both  crystal-violet inactivated 
vaccines  and  cell culture produced,  attenuated  live  vac-
cines  are  employed. 
The  inactivated vaccines  are  tested in  the  following  way: 
Conventional  tests  for  purity  and  innocuity.  Tests  in pigs 
only  randomly.  The  potency  not  tested regularly  - if it is 
tested U.S.  requirements  or  British codex will be  followed. 
In  general  the  VD  will inspect the  factory  and  use  "common 
sense". 
The  live attenuated vaccine  is  tested in pigs  very  nruch 
the  way  FMD  vaccines  are  tested in cattle, but  only  a  few 
timffiand  by  seed  lot.  There  are  a  number  of  absolute  re-
quirements: 
l)  No  clinical symptoms,  not  even  in stressed pigs  (corti-
son medication  for  6  days),  is  permitted. 
2)  No  fertility disturbance  and  no  pregnancy disturbance 
are  permitted.  In  addition it is desired,  that  no  tempera-
ture rise is demonstrable,  and  that no  virus  is demonstrable 
in tonsils  (in this way it may  be  possible  to distinguish 
between  field strains  and  vaccine strains).  The  same  de-
gree  of  immunity  should develop  in stressed  and  not stres-
sed  animals.  If these  tests are  passed,  then  an  identifi-
cation test in rabbit is carried out. 
Ireland 
No  production  and  no  specifications  for  imports,  which 
have  never  been  necessary  or permitted. - 66-
Italy 
The  production is carried out according  to  the direc-
tions of  the Ministry.  All batches  are  controled by 
Istituto Superiore  di Sanita in  Rome.  There  is  a  declared 
intention to fJllow  Pharmacopoeia  rules. 
U.K. 
No  production  and  no  special rules. 
4.  5.  2.  Innocuity Tests 
Belgium 
A  test for  innocuity,  potency  and  stability is carried 
out  in  8  piglets divided  in groups#  so  that  2  are  vacci-
nated  employing  normal  procedure,  4  vaccinated with  1/10 
dose  after an  exposure  of  the  lyophilized vaccine  to  37°C 
for  7  days#  and  2  serve  as  unvaccinated controls.  The 
vaccinations  are  tested by  challenge  (lo5ro50)  or sera-
neutralization tests  (titre.~32 taken  as  positive indica-
tion)  (details  given). 
France 
Three  piglets  known  to be without previous  exposure  and 
sensitive to classical swine  fever  are  given  inocula  of 
10  vaccine  doses.  The  animals  should  remain  in  good  health 
and  not respond with  elevated  temperature.  See  also  4.5.1. 
Holland 
See  under  4.5.1. 
Italy  · 
The  rules  are described  in the order of the Ministern 
della Sanita - Direzione Generale  dei Servizi Veterina-
ri n.  600.5/24486/Ag.  2494. 
4.  5.  3 ..  Potency Tests 
Belgium 
Potency  and  identity are  tested in rabbits  by  registering - 67-
temperature  rise after vaccination  (may  not  exceed  1°C) 
and  afterwards  by  checking  lack  of  temperature  change 
in the  vaccinated animals  (test specified) . 
France 
4  piglets are  given o.l dose  and  4  piglets  are  given 
o.ol dose  of  vaccine.  Two  animal?  are kept  as unvacci-
nated  controls.  After  14  days  all the  animals  are  chal-
lenged with  a  dose  of  virulent virus sufficient to kill 
unvaccinated  animals.  Vaccinated  animal  may  not  during 
14  days  respond  to  the  challenge with  temperatures  exceeding 
0  41.5  C  for  more  than  24  hours.  The  vaccine  dose  for  pigs 
must  contain at least  30  Po50. 
Holland 
Potency tests  are  carried out  in pigs.  The  vaccine  should 
contain  50-100  PD50  for pigs. 
Italy 
In Brescia the test is carried out  in pigs weighing 
30-40  kg.  The  vaccine is tested in dilutions  1/1, 
1/100,  1/200  and  1/400  (4  pigs  per dilution  and  4  con-
trols).  After  20-30  days  the  pigs  are  challenged by 
inoculation of l06ID50  for pigs  of virulent virus. 
The  pigs  are observed  for  2  weeks.  The  vaccine is ac-
cepted if 1/200  gives  full protection. 
4.  5.  4.  Former  U.S.A.  Requirements 
Although  U.S.A.  has  discontinued  the  production of clas-
sical swine  fever  vaccine  in  1971,  the  rules  employed until 
then  may  be  noted: 
l)  Standard requirements  for  inactivated hog  cholera vac-
cines.  A  blood  origin product  from  blood of  pigs  meeting 
the  general  requirements.  Virus  is inactivated in a"suitable 
way ... -68-
Safety  and  potency tests:  Pigs  are vaccinated  twice  sub-
cutaneously.  Controls  are  used  as  contact controls.  Chal-
lenge  virus must  give  grave  symptoms  and  post mortem posi-
tive diagnosis.  At  least  SO  per  cent of  vaccinated  ani-
mals  must  remain well  throughout  the  14  day  post-chal-
lenge  period and at least  80%  must  be  alive  and well at 
the  end. 
2)  Standard  requiremen~s for  Hog  Cholera  vaccine,  modi-
fied  live virus:  The  product  is prepared with  living mo-
dified virus  obtained  from  infected cell cultures. 
Potency:  Satisfactory vaccine  must  contain  enough  virus 
to give  a  titre of at least  103·°  FAD50±o.5  log  per  pig 
dose. 
Safety:  Pooled  samples  of  each  subserial are  pooled.  The 
pigs  inoculated with  2  ml  of  the  sample  must  not  show  any 
signs  of  adverse  reaction during  14  days. 
4.  5.  5.  Expiration 
Apparently  only  the French  rules  contain anything  about 
expiring dates.  There it is stated that the  lyophilized 
vaccine  should be  valid  for  12  months  and  should be  kept at 
2-lo
0 c. - 69-
4.  6.  V  a  c  c  i  n  a  t  1  on 
4.  6 .  1.  Rule~:;  for swine  fever  vRccina  tion 
Belgium 
Vaccination is  compulsory  for  crnrunercial  marketing.  For  the 
areas  of East- and  West  Flanders  and  Turnout vaccination 
is compulsory  for  all pigs.  A  vaccination certificate is 
issuedJ  and  the  animals  are  tagged  according  to specific 
rules. 
Denmark 
As  swine  fever  has  not  been  diagnosed  in  Denmark  since  1933, 
vaccinations  have  not  been  employed  or  even  planned.  Vac-
cination may  only  be  carried out with  permission  from  the 
Ministry  of  Agriculture. 
France 
Vaccination is not  compulsory,  hut  in certain threatened 
areas  (the  northern  area at the  Belgian border)  vaccina-
tion  has  been  encouraged  and  subsidized.  If the  need 
arises,  vaccination will become  compulsory. 
Germany 
Vaccinations  are  not carried out. 
Holland 
Vaccination will be  compulsory  when  an  emergency  is 
declared by  the  authorities. 
Ireland 
Vaccination is in principle  forbidden.  As  the  country has 
been  free  from  the disease,  no  license  for  import  of vac-
cine  or its use  have  been  issued  by  the  Department  of  Health. 
Italy 
Young  piglets must  be  vaccinated at the  age  of  60-70  days. 
Breeding  animals  must  be  revaccinated every  year.  The  ani-- 70-
mals  are  tatooed with the authorization number  of the 
vet.  after the vaccination.  It is not permitted  to 
employ  hyperimmune  sera togehter with the vaccine. 
U.  K. 
No  vaccination permitted except for  export animals. 
4.  6.  2.  Economics 
Belgium 
Vaccinations are payed  for  by  the  farmer.  Vaccination 
is encouraged  by  a  much  better indemnity  for vaccinated 
animals if slaughtering has  been enforced in connection 
with an epizootic. 
Denmark 
See  4.  6.  1. 
France 
For certain areas vaccination is encourages  and  subsi-
dized  by  the authorities. 
Germany 
In emergency cases  the vaccination would  be  paid  for 
by  the State. 
Holland 
Just as  for  FMD  vaccination in pigs  the  swine  fever 
vaccines  have  been  used only for  emergencies  and  are 
then paid for  by  the State. 
Ireland 
See  4.  6.  1. 
Italy 
As  long as vaccination remains  compulsory,  vaccination 
is without cost for  the  farmer.  The  vaccine is bought 
and distributed by  the Ministry  o~ Public  Health. - 71-
U.K. 
See  4.  6.  1. 
4.  6.  3.  Indemnities 
Belgium 
No  special provisions  are made. 
Denmark 
No  special provisions  are  made. 
France 
Responsibility  remains  t:.vi·th  the  producer. 
Germany 
For  the  emergency vaccination  the  State would  pay  endemnities 
for  damaqe  in  immediate  connection with  the vaccination. 
Holland 
In all cases  the  producer  or  the  seller remains  responsible 
for  the  product. 
Ireland 
See  4.  6.  1. 
Italy 
The  producer  remains  responsible  for  the  vaccine. 
U.K. 
No  special provisions  made. 
In table  4  the  general  economic  aspects  of  swine  fever 
vaccination in  the  Member  States  are  summarized. - 72-
Table  4 
Classical Swine  Fever Vaccine 
Economic  aspects 










The  farmer 
In certain areas 
subsidized  by  the 
State,  otherwise 
the  farmer 
The  State 
The  State 
The  State 
Indemnities  in case  of  vac-
cine-associated accidents 
paid  by: 
No  provisions  made 
The  producer 
The  State 
The  producer 
The  producer - 73-
4.  7.  P  r  o  p  o  s  a  1  s  f  o  r  Com m  u  n  i  t  y 
R  e  g  u  1  a  t  i  o  n  s 
4.  7.  1.  1.  Summary  of the present situation 
As  mentioned  in connection with proposals  for  Community 
Regulations  (3.  7.  1.)  the council directive of  26  June 
1964  (64/432/EEC)  and  the  amendments  following this di-
rective state,  that measures  must  be  taken  to eliminate 
differences  between  the health  requirements  of Member 
States.  It is still possible to maintain  severe restric-
tions  on  imports  and exports  or transits in order to safe-
guard the health of  man  and  animals  in acute,  defined si-
tuations,  but  such  possible right does  not  suppress  the 
duty  of providing conditions,  that may  result in the  rea-
lisation of  a  mutual  Community  policy.  It is the  duty  of 
the  individual Member  State to guarantee,  that animals 
for breeding or slaughter do  not  constitute  a  risk for 
spread of infection through  intra-community activity. 
The  actual situation,  both epidemiologically and  from  a 
regulation point of view,  varies  considerably  from  coun-
try,  but  in  none  of the Member  States  does  the  legisla-
tion  as  such  mention  a  general,  compulsory  vaccination. 
The  Belgian  rules  require  the  vaccination of pigs before 
marketing as  live pigs  and  for  general vaccination  in cer-
tain regions  of Belgium.  The  Italian order of  1967  con-
tains  the  requirements  for  compulsory  vaccination,  but 
in principle this is not against what would  happen  in 
other Member  States  in acute situations,  and  the  regula-
tion  from  1967  only  gives  the authorities  the  right to 
do  what  was  actually done.  The  other Member  States are 
either not  vaccinating at all or only  in certain regions 
or in acute situations.  It thus  seems  possible to for-
mulate  general regulations within  the  framework  of what 
is actually the  case  to-day. 
4.  7.  1.  2.  Standardization of  laboratory diagnosis 
Effective control of swine  fever  can  only be  obtained,  if 
the  sources of infection.and the  spread of infection are - 74-
properly traced.  The  specific clinical diagnosis of 
swine  fever  may  be  so difficult in  the  individual case, 
because  so  many  other infections  may  give  similar symp-
toms,  that it is quite  important  for  the  control that 
proper  laboratory diagnostic methods  be  set up  and  stand-
ardized.  The  Member  States  should standardize  the  diagno-
stic procedure  Lhrough  collaboration with  a  reference la-
boratory.  The  direct  immunofluorescence  test on  frozen 
tissue sections  of the  tonsils would  seem  to be  the  method 
of  choice.  Consequently  standard  conjugates  for this test 
should be  made  by  a  reference  laboratory,  and  techniques 
for  virus  isolation  and  virus  neutralization tests should 
also be  standardized. 
4.  7.  2.  Proposal  for Vaccination Procedure 
In principle,  the  situation should be  maintained  as it is 
to-day:  The  proper autjorities  in  each  country  should de-
cide,  if the situation calls  for  compulsory  vaccinations 
in certain regions  or for  a  whole  country.  The  decision 
should be  reached  in collaboration with  a  Community-· Ref. 
Lab.  and  the Nat.  Lab.  according  to rules worked  out  by 
Permanent Veterinary  Committee  procedures. 
The  European  Pharmacopoeia  Commission  rules  for  vaccine 
production  and  standards  are  under  discussion  and  are  not 
finalized.  It is of obvious  importance  not  to make  any 
suggestions within  the  Community,  which  are  in disagree-
ment with  the decisions  of  the  Pharmacopoeia  Commission, 
so  cooperation should be  as  close  as  possible with this 
commission. 
4.  7.  3.  Licenses  for Vaccine  Production 
4.  7.  3.  1.  Present Situation 
There  are  two  kinds  of  licenses:  l)  Establishment  licen-
ses  and  2)  Product  licenses.  The  general  rules  are  in fact 
not  very  different in the different Member  States,who pro-
duce  vaccjnes,but  in  Denmark,  Ireland and  U.K.  no  vaccines ,..,-
- i;)-
are  produced  and  in  cases  of  emergency  or for  other 
reasons  needed,  the  vaccines  would  be  imported.  Vac-
cines  are  produced  in Belgium,  France,  Germany,  Holland 
and  Italy,  and  they  are all controled by  the Nat.  State 
Institute authorized nationally to  do  so,  i.e.  in all 
cases  producer  and  controler are different establishments, 
and  both  domestic  and  foreign  vaccines  are  accepted in 
some  countries.  Thus  it should not be  very difficult to 
obtain  harmony  according to the  Rome  treaty for Classical 
Swine  Fever vaccines.  In principle it would  not be  very 
important,  if Germany  maintains,  that the  right to  issue 
establishment  licenses  remains  with  the  regional  (Lander) 
authorities.  Apparently  only  the  French  provisional  rules 
contain  anything  specific about  the  conditions  for  ob-
taining  an  establishment  license  (see  4.  3.  1.) 
In order to obtain harmony  within  the  Community  both 
the  Community  and  the National Authorities would  have  to 
establish regulations,  which  deal with other areas  than 
just the  vaccine  requirements  treated by  the  European 
Pharmacopoeia  Commission. 
4.  7.  3.  2.  Proposal  for  a  Community  License 
l)  Lstablishment  licenses  shall be  issued only  after in-
spection resulting in  a  determination  that the  establish-
ment  complies  with  prescribed standards. 
2)  A  product  license shall be  issued only  upon  examination 
of  the  vaccine  and  provided that the  vaccine  complies  with 
the  standards  prescribed  and  that the  establishment is ac-
cepted. 
The  details also regarding  License  Forms  etc.  could  be 
worked  out in such  a  way  that the  result could be  a  com-
mon  Community  License  valid for  all Member  States.  The 
norms  are  to  be  worked  out by  Permanent Veterinary  Committee 
procedure. - 76-
4.  7.  4.  Standardization of  Vaccine 
In  close  agreement with what  has  been  proposed  for  FMD  vac-
cines  (3.  7.  4.)  it is  suggested 1  that reference  labora-
tories  be  established,  preferably  as  an  extension of existing 
institutions. 
If  a  Community  License  is attempted it is essential that  such 
a  reference  lab.  exists 1  but even if National  Licenses  must 
still be  obtained directly,  it is still essential 
to have  a  reference  lab.  Such  a  laboratory  could 
work  together with  the National  Lab.  in  a  trial period 
(probably not  more  than  3  years)  with provisional ru-
les.  After this period  and after adjustment of  the  ru-
les  a  free  trade  for  vaccines  could be  established. 
Proposal:  The  reference  lab.  should  provide  information 
and  recommendation.  It should  provide  seed  lot virus  to  be 
used  as  challenge  in the  potency  tests. 
The  Nat.  Labs.  must  collaborate with  this  Ref.  Lab.,  and 
• 
mutual  decisions  must  be  followed  by  the  Nat.  Labs. 
Control  of production  and  issuing of  licenses.  The  establish-
ment  licenses  and  the  production  licenses  are  issued by  the 
Nat.  State  Lab.  or Authority  authorized to  do  so.  The  work 
should be  carried out  according  to rules  made  in  collabora-
tion with  the  Ref.  Lab.  Rules  should  be  set  up  for  this  col-
laboration. 
Community  Regulations  should  also state what part of 
the production controls  may  be  carried out by  repres-
sive control. 
Just as  for  the  licenses,release papers  should be  valid for 
all Member  States. - 77-
4.  7.  5.  Minimal  Requirements  for  Classical  Swine  Fever 
Vaccines 
4.  7.  5.  1.  Background  Papers 
Of  the  papers  available  for  study  French,  Italian,  Belgian 
and  Dutch  information  are especially  important  in  the  field of 
production control and  minimal  req~irements for  vaccines. 
As  the  European  :Pharmacopoeia  Commission  work  on  Swine  Fever 
vaccine  is not  finalizedJ  the  proposed  reference  l0boraotry 
should use  Lhe  material  obtained  so  far  as  guidelin~ in  the 
trial period,  unless  final  Pharm.  Com.  decisions  are  reached, 
in which  case  th2y  should  be  followed.  This  would  be  in  close 
agreement with  what  is  the  declared  intentions  of  the  coun-
tries,  in which  the  vaccine  is produced  to-day  and  also with 
the  European  Treaty  Series  No.  50,  where  it is stated  that 
the  rules  agreed  upon  by  the  Pharm.  Com.  should  be  the  offi-
cial standards  for  the  member  countries. 
The  following  papers  in particular are  employed  in the 
proposals  of  4.  7.  5.  2.: 
The  PA/PH/Exp.  15V/T  (73)31  (Comments  of  the Netherlands 
Delegation) . 
PA/PH/Exp.  15V/T  (74)  10  (proposed  by  Florent concerning 
control  by  titration of neutralizing antibodies); 
The  paper by  Precausta  and  Perrenot:  Titrage  des  anticorps 
neutralisants anti peste porcine classique par la methode 
d'immunofluorescence  (Rec.Med.  Vet.  (1973)  149  p.l567-1576), 
1he  conclusions  and  recommendations  on  diagnostic  methods 
for  swine  fever  by  the  group of the  Seminar  on  Diagnosis 
and Epizootiology  of Classical  Swine  Fever,  Amsterdam,  1975. 
PA/PH/Exp.  15V/T  (74)  4,  first rev.  (on  freeze-dried swine-
fever  (lapinised)  live vaccine), 
The  draft prepared for  the  Pharm.Com.  meeting  of April  25, 
1975  in Louviers  marked  H  bis of March  27,  1975:  Vaccine 
vivant  cryodessech~ centre  la peste  porcine  classiqu~ obte-
nu  en  culture cellulaire,  and 
The  Iffa Merieux paper of April  1974  on  Pestiffa:  Notice 
technique  concernant  la preparation et le controle d'un  vac-
cin vivant contre  la peste porcine  classique  A  l'aide de  la - 78-
souche  chinoise  "CL"  adaptee  A  la culture cellulaire. 
4.  7.  5.  2.  Proposals  for  Minimal  Requirements 
Freeze-dried  swine-fever  live vaccine  is  a  preparation ob-
tained  from  a  strain of  classical  swine  fever  virus,  which 
has  lost its pathogenicity  for  animals  of  the  porcine  species 
by  adaption  to other  animal  species  than  porcines  or  to cell 
cultures. 
The  vaccine  virus  strains 
The  vaccine virus  strain must  not  possess  any  observable re-
sidual pathogenicity for  pigs.  The  following  properties must 
be  found  for  the  seed  lots  of  virus: 
l)  Absence  of  pathological changes  in pigs,  in particul.ar 
the  abs~nce of  leucopenia. 
2 )  The  strain of virus  must  be  innocuous  for  the  foetus.  'l'hus 
neither infertility nor  still-birth nor  abortion  may  be  caused 
by  the  virus,  and  no  other  signs  of disturbance  of  pregnancy 
of  sows  may  be  observed. 
3 )  The  virus  should not be  transmissible  to unvaccinated pigs. 
(Apparently  spread of vaccine  virus  does  occur occa-
sionally  so  this  is  a  difficult property  to ensure). 
4
)  The  strain must  retain its apathogenicity  even  after 
six serial passages  in pigs. 
S)  The  virus  strain must  be  free  from  contaminating mi-
croorganisms,  including viruses. 
A  strain should be  chosen  that  may  be  differentiated 
in  the  laboratory  from wild strains.  Such  virus  strain 
markers  could be  growth  in certain ways  in special cul-
tured cell systems,  adaption  to  a  particular animal,  a 
certain temperature  optimum for multiplication,  specific 
reactions  to  immunofluorescence  tests or other ways.  The 
producer  should indicate  such  marker  for  the particular 
virus strain. 
In  order  to fulfill  the  demands  of  1-3  the  following 
tests  must  be  carried out: 
1.  Tests  on  pregnant  sows 
At  least 10  non-immunized  pregnant  sows  are  inoculated in-
tramuscularly  during the  first month  of  gestation with  a  dose - 79-
of  the  seed  lot corresponding  to  2  vaccinating doses 
(as  indicated by  the  producer).  A  group of at least 10 
unvaccinated  sows  of the  same  origin are  used  as  controls. 
The  seed  lot must  not  cause  any  disturbances  in  the gesta-
tion or have  any  detrimental effect on  the piglet. 
2.  Tests  on  pigs weighing  about  30  kg  carried out  for: 
safety,  potency,  non-diffusibility of  the  vaccinal virus, 
and  time  taken  to acquire  immunity. 
The  tests are carried out on  pigs  from  healthy herds 
weighing about  30  kg  and  free  from  specific antibodies. 
In  the  course  of  these  tests the  animals'  temperature is 
taken  twice  a  day. 
At  least  50  pigs  are distributed as  follows: 
Group  No.  1.  At  least 10  pigs  are  inoculated with  10  doses 
of  the  vaccine  (safety test); 
Group  No.  2.  At  least 10  pigs  are  inoculated with  1  dose  of 
the  vaccine  (test for  immunity  on  21st day); 
Group  No.  3.  At  least 10 pigs  are  inoculated with  1  dose  of 
the  vaccine  (time  taken  to acquire  immunity); 
Group  No.  4.  At  least 10  pigs  are  used  as  contact controls; 
Group  No.  5.  At  least 10  pigs  are  used  as  controls  of  the 
test virus. 
The  whole  series of  tests extends  over  8  weeks  and  is divided 
into  4  periods. 
First period  (adaptation of  the  animals  to the  laboratory). 
This  lasts  one  week  and  comprises  the  randomisation  of  the 
animals  to make  up  the  seed  lots mentioned  previously,  the 
weighing  and  the  elimination of parasites,  the determina-
tion of  the  absence  of antibodies  and  the  checking of the 
stability of  the  thermal  curve. 
Second  period  (immunization).  This  lasts  3  weeks.  Groups 
No.  1,  2  and  3  are  inoculated as  indicated above.  These 
animals  are  inoculated with  the  volume  recommanded  by 
the manufacturer.  In  the  case of  a  dose  or its multiples 
the  commercial  diluent is used  to make  up 'the  volume. - 80-
The  animals  are  then  reweighed.  During this  period  the 
thermal curve  is checked.  This  must  remain  normal  in all the 
animals.  The  period  of  immunization  for  the  10 pigs of 
Group  No.  3  used  to determine  ~hat  ~he time  ~aken to acquire 
immunity is only  7  days.  At  the  end  of this period  the ani-
mals  are  inoculated with  the quantity of  virus  specified 
below. 
Third period  (challenge).  This  lasts  two  weeks.  The  inununity 
of  the  pigs  (Group  No.  2)  is tested on  the  21st  day  by  ino-
culating a  quantity of virus  representing  at:  least 105  lethal 
doses  for  unvaccinated pigs,  whereby  death ensues-within 
7-14  days.  The  unvaccinated pigs  used  as  contact controls 
(Group  No.  4)  are  separated  from  the  vaccinated  animals  and 
challenged in the  same  way  15  days  later.  The  pigs  of Group 
No.  5  are  also inoculated with  the  same  quantity  of virus. 
During  this  third period 1  an  autopsy  is carried out  on  the 
dead  animals  to  confirm  the  causes  of death. 
Fourth  period  (post-challenge).  At  the  end of  the  third 
period,  the  surviving animals  are killed,  examined  for pos-
sible lesions  and  the  presence  or  absence  of test virus  is 
checked. 
The  seed  lot is  judged  on  the basis  of  the  following results: 
1.  The  form  of  the weightcurve before  and after vaccina-
tion. 
2.  The  reaction of  the  contact controls  and  the  unvaccinated 
controls. 
3.  The  potency. 
4.  The  time  taken  to acquire  immunity. 
1.  The  weight  curve  must  remain  unchanged  and  a  compari-
son between  the  mean  daily gains  must  not  disp~ay any  signi-
ficant difference  unfavourable  to  the  second period. 
2.  The  contact controls kept during the test in the  same 
place  as  the  vaccinated animals  must  react to the  lethal - 81-
challenge  in  the  same  way  as  non-vaccinated  controls  kept 
away  from  the  vaccinated  animals  and  take  the  same  time  to 
die. 
3.  For  each  type  of  treatment  (Groups  1,  2  ana  3)  those 
animals  shall be  regarded  as  protected who  have  survived 
the  test without  any  notable  change  in their thermal  graph 
and without displaying  any  acute  lesions  under  necroscopic 
examination after being  slaughtered on  the  fifteenth day. 
The  presence  of  scarry  lesi0ns will be  tolerated,  but if the 
test virus  is observed to be  present in  an  organ  the  seed 
lot must  be  discarded.  All  the vaccinated  animals  must 
comply with  this  requirement. 
4.  The  time  of onset of  immunity  in pigs  after vaccina-
tion with  1  vaccinating dose will be  7  days.  In this test, 
those  surviving animals  shall be  regarded  as  protected 
0  whose  temperature  does  not  exceed  41.5  for  more  than  24 
hours.  All  the  vaccinated animals  must  comply with  th:is 
requi·ement. 
Requirements  for  each  batch  of  finished  vaccine 
Each  batch shall be  prepared  from  a  seed lot of virus,  which 
complies  with  t_he  above  specifications  for  the  vaccine vi-
rus  strains. 
1
1he  vaccine batch  must  not be  more  than  5  pass~es past the 
seed lot tested according  to these  requirements. 
Each  batch  of  vaccine  must  comply  with  the  Pharm.  Com.  ste-
rility tests. 
Innocuity  tests are carried out by  intramuscular  injections 
in  3  susceptible piglets weighing  about  30  kg  and  littered from 
sensitive  sows.  Each  piglet receives  10  ctoses  of  the  vaccine 
reconstituted as  indicated  on  the  label.  The  animals  are  ob-
served for  21  days.  The  thermal  graph  must  remain  normal,and 
the  animals  must  remain  in apparent  good  health  and  display 
normal  growth. 
Potency  tests  are  carried out  in  two  ways: 
l)  It must  be  shown  that the  vaccine  contains  a  minimum  of - 82-
10 protective doses  for pigs.  The  test is carried out by 
intramuscular injections  of  1/50 of  a  vaccine  dose  into 
4  piglets weighing  about  30  kg. 
2 )  The  thermal stability of  the  vaccine  must  be  tested 
by  intramuscular injections  into  4  piglets weighing  about 
30  kg  of  1  dose  of vaccine,  which  has  been  kept  for  one 
week  at 37°c. 
3)  2  piglets  of  the  same  age~ weight  and  origin are  used 
as  controls.  After  14  days  all the  animals  are  challenged 
and  examined  in the  same  way  as  described  for  potency testing 
of  the  seed  lot.  The  vaccinated  animals  must  be  protected  and 
may  not  show  lesions  or  rise  in  temperature.  The  two  control 
piss  die. 
By  Permanent Vet.  Conun.  procedure  and  in collaboration with 
the  reference  laboratory it may  be  decided,  that  some  con-
trols are  carried out by repressive controls,  and  that al-
ternc!tive  rt;1ethods  not  employing pigs  may  be  employed  jn cer-
tain cases. 
storage 
The  lyophilized vaccine is stored  in darkness  at 2-6°C. 
The  vaccine must  be  used  immediately after reconstitution  .. 
Expiration date 
The  vaccine  may  be  expected to retain its potency 
for  12  months  from  the  date of  the  last test for 
potency if stored under  the prescribed conditions. 
4.  7.  6.  Vaccination  programmes 
The  vaccines  employed  to-day  reduce  the  disease  inci-
dence,  but there is  no  assurance  that  SF  virus  can  be 
eliminated,  while  programmes  of vaccination  continue. 
In  some  countries  vaccination  must  be  used  to control 
swine  fever effectively at present.  The  available  infor-
mation  indicates,  that the  vaccine  virus  strains  employed 
are genetically stable  and  do  not,  or only  occasionally, 
spreaq  from  vaccinated pigs. - 83-
Information  about  the possible persistence of virus  in 
vaccinated  pigs  is rather  incomplete,  but it has  been  re-
ported,  that the  virus  may  be  present in pigs  six months 
after vaccination. 
A  nu~Jer of  questions  regarding  the  vaccination of pig-
lets especially  from  immunized  mothers  are  not sufficient-
ly elucidated.  The  abov~ mentioned  problems  should be  kept 
in mind,  when  vaccination  progranunes  are decided. 
For vaccination programmes  the  following  is proposed: 
The  animals  should be  vaccinated according  to what  is 
prescribed by  the  producer. 
Identical  programmes  should be  employed  in all the  Member 
States  in  accordance with  the  decisions  reached  through 
Permanent Vet.  Com.  procedures.  The  questions  should be 
studied with  the  goal  in mind  of  harmonization,  so  that 
identical situations  are handled  in  the  same  manner  in all 
Member  States. - 84-
5.  NEWCASTLE  DISEASE  VACCINE 
5.  1.  I  n  t  r  o  d  u  c  t  i  o  n 
Control  and  prevention of Newcastle  Disease  in domestic 
poultry  flocks  within  the  EEC  depends  on  a  number 
of  factors  besides  the nature of the virus,  e.g.  the 
pattern of production  and  the  movements  of wild birds, 
domestic poultry,  eggs  and  poultry meat.  To  this must 
be  added  the quality of the  vaccines  and  the  character 
of the vaccination programmes. 
In  the tropic areas  natural  reservoirs of Newcastle 
Disease virus  (NDV)  exist.  Through  the  import of wild 
birds  foreign  virus  types  are  introduced into domestic 
poultry populations.  This  introduction of virus  some-
times  of high  virulence  may  overcome  the effects of tra-
ditional vaccination programmes. 
In  the  integrated production  system of  EEC  prevention 
against exotic infections  should take  the  form of con-
trol of  importation of exotic birds,  live poultry,  eggs 
and  poultry meat  from  Third Countries,  but it is at 
least as  important to  reduce  the  spread of  field virus 
within the  Community.  Theoretically  an  efficient solu-
tion would  be  to prohibit  Intra-Community  trade.  In 
practical terms,  however,  this is only partly  a  solution, 
as  the  regional  problems still exist,  and  some  material 
will  always  pass  frontiers.  In  addition this solution 
will be  neither desirable nor  legal.  Consequently other 
means  of safe-guarding the  flocks  must  be  introduced to 
reduce  the  risk of  spreading N.D.  infections.  Hanson  has 
(R.P.  Hanson  (1964);  Newcastle  disease virus:  An  evolving 
pathogen,  Madison,  Univ.  and  Wisconsin  Press)  reviewed  the 
problem. 
5.  1.  1.  Newcastle  Disease Virus 
NOV  belongs  to  the  paramyxoviruses.  It contains  RNA  in  a 
nucleoprotein helix surrounded  by  an  envelope  containing 
lipids.  On  the  surface  are projections  containing haemag-- 85-
glutinin  and  the  enzy~e neuraminidase.  The  size is  around 
100-200  nm  in diam.,  but filamentous  particles occur. 
Only  one  serotype is  found 1  but it has  been  reported, 
that immunological differences  amongst  strains exist, 
anyway. 
Virus  infectivity is sensitive to  lipid solvents  and  is 
heat  labile  and  unstable  at high  and  low  pH.  It has  long 
been  considered,  that NOV,  contrary  to other paramyxoviru-
ses,  may  withstand  drying.  Consequently  the  virus  may  re-
main  active  in the  dust  of  infected  farms,  but  laboratory 
studies  do  not  support this. It has  therefore been  sug-
gested,  that previous  findings,  based  on  epidemiological 
evidence 1  that chickens  may  become  infected in deserted, 
cleaned buildings  long  after ND  cases,are  really misinter-
pretations  of  evidence.  The  expla.nation ma.y  be,  that sub-
clinically infected chickens were  introduced in  the  cleaned 
farm  rather than  recurrency  has  resulted  from  insuffi-
cient cleaning and  disinfection,  so  that the  virus  sur-
vives  in the building and  surroundings. 
5.  1.  2.  Newcastle  Disease 
Synonyms:  Avian  pneumo-encephalitis,  fowl-pest  (which  then 
would  include  also  fowl  plaque,  a  disease  caused by  avian 
influenza virus). 
A  fatal disease  may  be  caused in birds by  NDV.  Respiratory 
or  nervous  symptoms  may  be  seen  and  sometimes  both nasal 
discharge  and watery  diarrhoea  may  be  seen  also.  Milder 
str~ins  (the  lentogenic  ones)  occur as well as  more  viru-
lent strains  (the  velogenic  ones).  Th~ milder strains  cause 
low  mortality 1  but  may  affect egg  production.  The  infec-
tion may  be  spread  through  drinking-water  or  may  be  air-
borne.  The  respiratory tract is considered the  most  im-
portant portal of entry rather  than  the  intestinal tract. 
Virus  has  been  isolated  from eggs,  from vaccinated hens. 
Healthy  carri~s are  frequently  found. - 86-
5.  1.  3.  Control 
Whole-sale  slaughter or vaccination are  the  two  alterna-
tives  for  control.  The  vaccinations  are  now  usually 
carried out with  live attenuated virus  vaccines,  but  some 
inactivated vaccines  are  used  in special situations. 
Various  procedures  of  prevention  and  control are  applied 
in different countries  to  reduce  tne  losses  due  to New-
castle Disease.  The  methods  employ9d  depend  on  the  pro-
duction pattern and  the  geographical situation.  Vaccina-
tion is usually preferred,  because it establishes 
protection quickly  and  easily without  expensive 
improvements  in  the  standards of hygiene.  If path-
ways  are  opened  for  infections between  flocks  and 
countries  however  a  permanent  risk of spread of new 
exotic virus  types  from  the outside will result.  In 
addition  a  spread of classical virus  infections  might 
cause  a  break  through  a  low barrier of  immunological 
protection  and  result in disease. 
The  combined  influence of  the  spread of  virus  from 
infected flocks  followed  by  more  or  less  systematic 
employment of  vaccines  of  varying quality  leads  to  irre-
gular fluctuations  in  the  health  situation in  many  poul-
try populations.  The  result is  an  unbalanced  animal  pro-
duction  causing  economic  loss  or  bad  economy  due  to 
overproduction. 
The  ideal solution is the establishment  and  maintainan-
ce of poultry without  NDV  infections.  This  principle is 
followed  in certain countries  by  the  combined  activity 
of producers,  who  build up  closed  flocks  and partici-
pate  in  a  common  health  scheme,  in which  breeding  farms, 
development  and  production  establishments operate with-
in  a  vertically integrated and  closed system.  Efficient 
control  and  elimination by  slaughter of  flocks  in which 
ND  is diagnosed is  an  essential part of the  scheme.  This 
system functions  in  some  areas  and  should be  considered 
the  long-term solution  for  a  number  of  European  areas, 
where  the only realistic solution of the problems  of 
protecting many  Community  flocks  is vaccination. - 87-
This  stresses  the  importance  of  getting  a  better quality 
of vaccine  and better 1  more  uniform vaccination proce-
dures,  so  that  a  permanent high  immunity  may  be  obtained 
for egg-layers  and  a  good  protection of broilers before 
slaughter.  A  svecial problem is the possibility,  that field 
virus  may  be  disguised in vaccinated flocks,  but at least 
the  concentration of  infective virus  may  be  reduced in the 
carcass.  If the  carcasses  are processed without head,  legs 
and viscera,  this  danger  may  be  further diminished. - 88-
5.  2.  L  e  g  i  s  1  a  t  i  o  n  a  n  d  r  e  g  u  l  a  t  i  0  n  s 
f  0  r  v  a  c  c  i  n  e  s  a  g  a  i  n  s  t  N  e  w  c  a  s 
D  i  s  e  a  s  e  i  n  t  h  e  d  i  f  f  e  r  e  n  t  H  e  m 
s  t  a  t  e  s.  A  r  e  v  i  e  w  0  f  r  e  l  e  v  a  n  t 
d  0  c  u  rn  e  n  t  s 
Belgium 
""  Arret~ royal  du mars  1974,  portant des  mesures  de  police 
sanitaire relative  A la peste aviaire et A la pseudo-peste 
aviaire.  This  regulation which  contains  rules  and  regula-
tions  regarding control measure(in  Bull.  Sanitaire No.  7, 
April  1974 1  p  84-99)  against  the  disease  including vacci-
nations1  but nothing  about  the  vaccines. 
The  control of  NDV  vaccines  is  covered by  the  general  le-
gislation requiring  the  control of all vaccines  by  the 
Vet.  State Lab. 
Denmark 
Apotekerloven  a£  Juli  1962  (Drug  Act) .  Bekendtg¢relse  om 
foranstaltninger til bekcempelse  af ondartede  smitsomme 
sygdomme  has  fjerkrCE  (August  1963)  (Order  on  measures  for 
the  coDtrol  of notifiable  communicable  poultry diseases). 
This  order is in general  terms  rather close  to  the  Bel-
gium  regulation,  except  that the  vaccinations,  which  are 
potentially possible,  are  not encouraged.  They  have  in 
fact  never been  permitted.  In  the  sporadic cases  that have 
happened ,  the  disease  spread has  been  stopped 
by  slaughter. 
France 
No  regulations exist.  While  waiting for  Pharmacopoeia 
decisions  provisional rules  have  been  issued by  the Mini-
stry of Agriculture.  These  are  concerned  with  standards 
and  control  tests  for  inactivated and  live attenuated 
vaccines. 
The  general rules  are  in  the  Code  d~ la  Sant~ Publique, 
articles  L  611-L  617. 
Germany 
Verordnung  tiber  Sera  und  Impfstoffe  nach  §  l7c  des  Vieh-
t  1  e 
b  e  r - 89-
seuchcngesetzes  (Februar  1973). 
Ausflihrungshinweise  zur Verordnung  crber  Sera  und  Impf-
s toffe  (Marz  19 7 3) • 
Verordnung  zum  ~)~hutz  gegen  die  GeflCigelpest  und  die  New-
castle Krankheit  (Geflcrgelpest-Ver9rdnung)  von  Decenber 
19 72. 
Richtlinien  filr  die Herstellung  und  Prfifung  von  Lebend-
vakzine  zur  Immuniesierung  gegen  atypische Gefltigelpest 
(Newcastle  Disease)  (undated material  received  from 
Poul-Ehrlich-Institut,  September  1974). 
Staatliche  Prilfung  von  Impfstoffen  gegen GeflUgelpest 
(Febr.  1969,  from  Staats-Anzeiger filr  das  Land  Hessen  p. 374). 
In principle Germany  is also  waiting for  Pharmacopoeia  rules. 
Holland 
Verordening N.C.D.-bestrijding,  Marts  1974  (Regulation  on 
Newcastle  Disease  control),  which  contains  rules  for  com-
pulsory  vaccinations  and  serum testing of  poultry. 
Uitvoeringsbesluit  I  and  II of Verordening  N.C.D.- bestrij-
ding  1974  containing information  about  how  the  regulation 
is  useo in practice.  Stichting Gesundheidzorg  voor  Dieren 
of Jan.  1975:  Instruktie dierenartsen  ten  aanzien  van  de 
Uitvoering N.C.D.-entingen,  which  contains  the  instruc-
tions  for  the  veterinarians  regarding  the  NDV  vaccinations. 
The  Vet-Service  decides  what  strains and what  kind of pro-
ducts  may  be  used.  The  accepted  firms  are  mentioned  by 
name  (including  a  large  Belgian  firm),  and  they  have 
accepted  inspection by  Vet.  Department-inspectors,  who 
sample  for  repressive control.  The  repressive  control 
functions  in such  a  way,  that if 3  lots out of  5  lots 
were  not  found  satisfactory,  a  preventive  control  is 
enforced,  until the product is  up  to  standard.  If this 
does  not  occur,  the producer  may  loose his  license. 
Ireland 
Animal  Remedies  Act  of  1956.  Diseases  of  Animals  (Disinfec-
tion)  Order of  1931. - 90-
Imports  of  vaccine  would  be  by  permission  from  the  De-
partment of  Health  (after consultation with  the  Depart-
ment  oE  Agriculture),  but  a  license has  never  been  issued. 
Italy 
L.  Ravaioli,  z.  Orfei 1  M.  Granieri:  Controllo dei sieri, 
dei  vaccini  e  dei  prodotti diagnostici per  usa  veterlnaria, 
Istituto Superiore di Sanita,  Roma  1964.  The  vaccine  must 
contain at least  l06or50/dose. 
F.  Cessi  and  L.  Nardelli:  Requirements  for testing oil 
emulsion  inactivated Newcastle  Disease  vaccine  (1974)) 
about  the  controls  for  inactivated vaccines. 
The  general  rules  require that only  the first batch of the 
producer be  controlled by  the Istituto Superiore di Sanita. 
After this stage official control is done  only irregularly. 
The  systematic  control is  done  by  the  producer. 
Luxemburg 
Follow  Benelux-rules. 
U.K. 
The  Medicines  Act  (1968)  which  requires  both manufacturing 
establishments  and  each  product  to be  licensed.  Manufac-
turers  are  subject to  inspection  and  have  to have  ade-
quate  premises,  methods  and  records.  Each  product has  to 
be  shown  to be  safe,  effective  and  of  satisfactory quality. 
British Vet.  Codex  1965,  Supplement  1970. - 91-
5.  3.  P  r  o  d  u  c  t  i  o  n 
5.  3.  1.  Identification of  the  Producer 
Belgium 
Authorized prjvate  firms. 
Denmark 
No  production.  Vaccinations  have  never been  permitted,  but 
vaccine would  be  importEd if considered necessary  for  emer-
gencies  by  the Vet.  Auth. 
France 
Authorized private  firms.  The  authorization is obtained 
after the  testing of  the  trial products  and  after inspec-
tion of  the  premises. 
Germany 
Authorized private  firms. 
Holland 
Authorized private firms. 
Ireland 
No  production.  If considered necessary  by Vet.  Auth.  import 
would  be  permitted.  This  has  never happened. 
Italy 
Both  the  Publ.  Health  Institutes  and  private  firms  are::  autho-
rized to  produce. 
Luxemburg 
Is part of  a  Benelux-agreement. - 92-
U.K. 
Private  firms  who  have  obtained  a  license to  do  so. 
According  to  the  Codex  live vaccines  are  not permitted, 
but  Centr.  Vet.  Lab.,  Weybridge  informed  (in Sept.  1974) 
that only  lentogenic strains are  allowed.  This  means  that 
the strains Hitchner  B  1  and  La  Sota have  been permitted 
and  now  are  the only permissible. 
5.  3.  2.  Licenses  for  establishment 
It seems  that in all the  producing  countries  (Belgium, 
France,  Germany,  Holland,  Italy and  U.K.)  the  authoriza-
tion is  given  by  the  State after control  of  the  product 
and  inspection of  the  pr~mises.  Only  in Germany  the  establish-
ment  license is given  by  the  local  authorities  (Bundesland-
authorities),  but this  remains  a  theoretical difference,  as 
the  State Lab.  has  the  production control  even  for  the  pri-
mary  product. 
5.  3.  J.  Licenses  for  Release 
Belgium 
The  State Vet.  Lab.  releases  vacc  i lll"S  a[  ter los ts . 
Denmark 
Vaccinations  may  only  be  performed  with  vaccines,  whi.ch 
have  been  imported  by  permission  from  'he Hinlstry  of  Agri-
culture,  and  they  are  only  obtainable  from  the  SLate  V0t. 
Serum Laboratory.  Such  permits  have  no·t  been  given. 
France 
Each  vaccine  batch whether  French  or  imported  ir;  sampled, 
but  tests  are  carried out  at random.  The  State  Lab.  re-
leases. 
Germany 
Poul-Ehrlich-Institut  (Bundesamt  fur  Sera  unCJ  Impfstoffe), 
i.e.  the  State Lab. 
Holland 
The  State Lab.  (Centraal  Diergoneeskundig  InstituuW-- 93-
Ireland 
The  State would  release by  giving permission  for  imports. 
Such  permission has  never  been  given. 
Italy 
The  Sta.te  Lab.  (Istituto Superiore  di  Sanita,  Roma). 
U.  K .. 
The  Stc.te  Lab.  (The  Central Vet.  Lab.,  Weybridge) . - 94-
5.  4.  C  o  n  t  r  o  1  i  n  g  A  u  t  h  o  r  i  t  i  e  s 
In  table  5  the  information  on  the producers  and  the 
controling authorities is collected.  Whereas  the 
establishment  licenses  in all the producing countries 
require that the  samples  from  the primary  production 
be  tested,  production  control is often carried out 
either by  repressive control or by  testing the  col-
lected samples  at random or even  by  sampling  less 
frequently. - 95-
5.  5.  T  h  e  C  o  n  t  r  o  1  s  a  n  d  S  t  a  n  d  a  r  d  s 
r  e  q  u  i  r  e  d 
5.  5.  1.  General  Rules 
Belgium 
All  vaccines  are  controlled on  quality,  innocuity  and 
quantity of  immunizing  particles,  but  the  specific re-
quirements  are  not stated.  There  is  a  special Benelux-
agreement  to  have  the  same  quality  and  controls  and  a 
declared intention of  following  Pharmacopoeia rules.  Appa-
rently  only  the  lentogenic,  live vaccines  are  employed 
(the  LaSota or  the  Hitchner  B  1  strains).  It  has  not 
been  stated  whether other strains are  permi~sible. 
Denmark 
No  specifications.  Imports  have  never  been  permitted. 
France 
Inactivated vaccines. 
The  vaccine  may  contain  an  approved  anti-microbiological 
compound  and  must  pass  conventional sterility tests. 
Tests  performed  on  live,  attenuated,  lyophilized vaccines. 
The  vaccine  is prepared  from  a  lentogenic strain in eggs 
or  in cell cultures.  In both  cases  the  absence  of  speci-
fic  avian  pathogens  must  be  demonstrated.  The  virus strain 
must  have  an  index of  neurovirulence  o.25  (the  index  spe-
cified).  This  test is only obligatory  for  seed lots. 
The  purity of the  vaccine  virus  is tested through  a  neu-
tralization test  (described in detail)  in embryonated  eggs, 
which  shall not  show  any  abnormalities  or  possess  hemagglu-
tinins.  The  vaccine  must  also be  tested for  encephalomyeli-
tis virus,  but  for  leucosis  (COFAL  test)  and  Marek  disease 
(serum neutralization tests on  chicken  42  days  after vacci-
nation with  a  10  fold vaccine dose).  It is sufficient to 
test the  seed  lot.  Tests  for  mycoplasma  and bacteria are 
also carried out. - 96-
Germany 
Inactivated vaccines. 
The  vaccine  must  primarily be  tested by  the producer,  but 
under  the  supervision of  a  State representative.  The  vac-
cine  must  contain  a  bacteriostatically active  substance 
which  must  be  declared. 
Sampling is described  in detail in the  legislation.  The 
control tests by  the State are  concerned with sterility, 
innocuity of the  antibacterial substances  (tested in  2 
mice),  residual  virus  activity  and  potency.  The  produc-
tion  records  and  test results obtained by  the producer 
must  be  submitted to the State control institute. 
Tests  on  attenuated live vaccine. 
For  the  vaccine  the  strain Hitchner  Bl  or another  corre-
spondingly  lentogenic virus  strain must  be  employed.  The 
virus  may  be  produced  in  eggs  or in cell cultures,  in 
both  cases  the host  system must  be  free  from  avian patho-
gens  (specified) .  The  SPF  state must  be  controled ny  tests 
each  month  in  the  chicken  flocks  used.  The  test records 
must  be  kept  for  inspection.  The  production  must  take 
place in  rooms  and with  equipment,  which  are  not  employed 
for work  with other viruses,  bacteria or  fungi. 
The  seed virus  to be  employed  as  vaccine  must  be  controled 
for purity,  innocuity  and  potency.  The  identity of  the vi-
rus  is controled by  establishing  a  neutralization  index 
employing  a  NOV-antiserum  and  inoculations  in eggs.  The 
presence of  contaminating viruses  is controled by  pas-
sing neutralized material  in  eggs  (details  are  given). 
The  avirulence of the  NDV  strain is  checked  through  a  de-
termination of  a  neurovirulence  index  (in  the  same  way 
as  the  French test and  as  Hanson  (1956)  Am.  J.  Vet. 
Res.  17,  16).  Only  lyophilized vaccine with  a  minimum  of 
additions  may  be  marketed.  The  finished  vaccine is tested 
for  contamination with bacteria,  fungi  and  mycoplasma. - 97-
Holland 
No  special  inforaation received,  apart  from  the  fact  that 
a  Benelux  agreement exists,  and  the  Pharm.  Comm.  is close-
ly  followed. 
Ireland 
No  requirements  specified.  No  impo~ts have  been  permitted. 
Italy 
Few official regulations  for  controls or tests exist. 
The  Brescia institute follows  the British Codex  and  the 
material published by  Cessi  and Nardelli  on  the  inacti-
vated vaccine.  These  would  give  a  more  strict control 
than  the official tests.  The  internal control by  the 
Brescia institute is carried out  in  the  following  way: 
Inactivated vaccines with  adjuvants  are prepared in  11 
day  old embryonated  eggs.  The  allantoic harvests  are 
clarified by  centrifugation  and  inactivated using beta-
propiolactone.  The  inactivated virus  is emulsified 
with  mineral oil to which  emulsifier is added  (Freundt's 
incomplete  adjuvant).  The  vaccine  is tested for steri-
lity,  emulsion stability and  viscosity.  Live  attenua-
ted vaccines  are  tested for purity  as  follows:  Ten 
chickens  are  vaccinated  and  may  not  show  any  signs  of 
disease  during  a  15  day  period.  In  eggs  3  different 
routes  are  employed  (each  for  5  eggs)  for  inocula-
tions  of micture of virus  and  antiserum.  Except  du-
ring the  first  24  hours,  the  embryos  must  not  die  or 
react in  any  way  to the  inoculation. 
The  controls which  are  carried out  by  the Istituto 
Superiore di  SanitA  for  the  registration of  a  live 
attenuated virus  vaccine  are  always  carried out  in 
SPF  eggs. 
U.K. 
Tests  for  inactivated vaccine. 
The  vaccine  may  be  prepared  in  eggs  or cell cultures  and 
inactivated with  a  suitable agent  (e.g.  beta-propiolactone 
or  formalin).  Conventional  sterility tests  are  carried out. 
Test  for  live attenuated vaccines. 
The  chicken  flocks  must  be  SPF  for  all the  important avian - 98-
pathogens  (tests specified). 
Seed  virus must  be  tested for  extraneous  agents  like  fungi, 
bacteria,  mycoplasma  and  viruses.  Controls  for  avian ence-
phalomyelitis  virus  and  Marek  disease virus  and  other agents 
are  carried out by  inoculations  in  5-6  days  old  and  14  days 
oldchickens  employing  10  times  the  intended vaccine  dose. 
A  leukosis  test is  made  in chick  embryo  fibroblast  cultures 
and,  in addition,  inoculations  in  embryonated  eggs  using 
3  different routes  are prescribed  followed  by  a  further 
embryo  passage.  No  deaths  or abnormalities  may  occur. 
For  vaccines  ~sing the  Hitchner  Bl  strain the  vaccine shall 
be  shown  to have  an  ICPI  of  not greater  than  o.3.  For  the 
La  Sota strain the  tests  are essentially the  same  except 
for  details  of  the  innocuity tests  (see  5.  5.  2.) .If a  pa-
renteral administra·:icn is intended,the  tests are  essen-
tially similar. 
5.  5.  2.  Innocuity T0sts 
France 
Inactivated vaccine. 
Innocuity is tested by  intramuscular  inoculation in at 
least 10  chickens  (3-6  weeks  old)  employing  2  vaccine 
doses  per  animal.  The  ani~als are  observed for  3  weeks. 
All  animals  must  survive  and  remain  healthy. 
Live  vaccines. 
A  group  of  20  chickens  is vaccinated  and  as  many  are kept 
as  controls.  All  animals  must  survive  and  remain  healthy. 
Germany 
Inactivated vaccine. 
The  vaccine  is tested by  letting  5  chickens  receive  each 
10  ml  of  vaccine.  They  should  remain well,  with  no  signs 
of  NDC.  The  same  applies  for  inoculations  in erooryonated 
eggs.  Details  in  the  tests are  given. 
Live,  lentogenic vaccine. 
In  addition  to the  vaccination experiment mentioned  under - 99-
potency-testing the  following test is carried out:  Intra-
muscular  inoculations  are performed of o.l ml  of  a  1/So 
dilution into  20  days  old chickens,  which  must  remain 
well  and  alive after  14  days. 
Italy 
Inactivated vaccine with  adjuvants.  Innocuity is tested 
by  inoculation in  25  10-day  embryonated  eggs  to  control 
the possible  residual virus  activity both  in  inactivated 
virus  suspension  and  finished  vaccines  (both  living and 
dead  embryos  are tested as  pools).  One  passage of pooled 
material  should give  a  product without HA-activity. 
A  test in  20  chickens  is carried out  employing  intramus-
cular injections with  1  ml  vaccine.  No  abnormal  reactions 
may  develop  during  the  observation period  (14  days). 
Live,  attenuated vaccines  are  tested for  innocuity by 
vaccinating  25  5-6  day  old chickens  from  SPF  eggs  accord-
ing  to  the prescribed method.  They  are observed  for  21 
days,  and if more  than  8  per cent die with  respiratory or 
nervous  symptoms  of disease,  the  vaccine  is not  accepted. 
Characterization of the  vaccine  virus  is obtained by  de-
termination of the  index of  intracerebral pathogenicity 
(!PI)  and  the  index of  intravenous  pathogenicity  (IPIV). 
U.  K. 
Inactivated vaccine.  Innocuity tests are  carried out  in 
eggs  and  chickens.  The  materials  from  eggs  are  collected 
in  two  pools:  one  from  the  eggs  with  live embryos  and  one 
from  the  eggs with  dead  embryos.  Both materials  are passed 
into new  eggs,  which  must  be  free  from  HA  reaction after 
harvest.  The  chickens  must  remain  healthy. 
Live,  attenuated vaccines.  For  the Hitchner strain in-
tranasal instillation at the  field strength is  applied 
to  25  day  old SPF  chickens.  No  more  than  two  deaths  and 
no  respiratory or nervous  symptoms  after  21  days  may  oc-
cur. 
The  test for  the  La  Sota strain is essentially the  same, 
but  25  SPF  chickens  of  age  10-21  days  are  employed,  and 
the  surviving birds  shall be  challenged. - 100-
5.  5.  3.  Potency Tests 
France 
Inactivated vaccine. 
Potency  is tested by  vaccinating  20  animals  in the pre-
scribed way.  After  14-21  days  the  vaccinated animals  as 
well  as  a  corresponding control group are given  l05Ln50  of 
a  virulent NDV\  The  virus  should kill loo per  cent of 
the  controls,and  90  per cent of  the  vaccinated  chicken 
must  survive without  any  signs  of disease. 
Live,  lentogenic vaccine. 
A  group of  20  chickens  are  vaccinated  and  as  many  are 
kept  as  controls.  They  are  challenged with  l05LD50  of 
virulent NDV.  The  dose  should kill all the  controls,  and 
90  per  cent of  the  vaccinated chicken must  survive without 
any  symptoms  of  disease~ 
The  titre of infectiosity may  not be  lower thml06In50 
per  vaccine  dose.  This  test is carried out in embryona-
ted eggs  through  HA  demonstration. 
Germany 
Inactivated vaccine. 
Potency is tested using  160  2-week-old  chickens.  Of  these 
chickens,  100  chickens  are  employed  for  testing a  standard 
vaccine  (employing  2  doses  with  a  factor  10 in between) 
for  comparison.  Of  the  remaining  animals  50  are  employed 
for  the  vaccine  to be  tested,  and  10  animals  serve 
as  unvaccinated controls.  After  14  days  a  challenge  dose 
6  of  5  x  10  Lo50  of  virus  is given,  and after  a  further  10 
day'  period  the  control  animals  must all have  died.  The 
vaccine  tested must  give  a  protection between  the  one  ob-
tained with  the  two  standard vaccine·at the  doses  em-
ployed  (details  given). 
Live,  lentogenic vaccine. 
The  potency of the  virus  harvest is tested in eggs.  The 
titre must  be  1o8 · 5;o.l ml  before  lyophilization.  The  fi-
nished vaccine is tested for  potency  as  follows: - 101-
A  dose  sufficient for  100  animals  must  contain  4  x  l08Io50 
measured  in eggs.  A  vaccination experiment is made  in  20 
3-7  da.y  old chickens  employing  the  vaccination method  pre-
scribed by  the  producer.  The  animals  must  remain well. 
After 14-21  days  the  vaccinated animals  and  a  corresponding 
group of unvaccinated  animals  are  challenged using  104 
egg  ro50  of  a  virulent strain of  NOV.  Out  of the  20  con-
trols  18  at least must  show  typical  NO  symptoms  and at 
least 18  of  the  20  vaccinated must  be  protected during 
a  14  day  observation period. 
Italy 
Inactivated vaccine with  adjuvants. 
Potency is tested by  a  titration of the  vaccine  employing 
1/25,  1/50  and  1/100 of  the  recommended  dose.  A  challenge 
5  of at least  2  x  10  egg  LD50  of Herts  33  strain is given 
to  the  75  vaccinated.and at least 10  unvaccinated  con-
trols, which  must all die  during  a  10  day  period after 
challenge.  By  a  probit analysis  a  strength of  at least 
75  PDr- must  be  found  for  the  vaccine.  The  lower  95%  con-
-~o 
fidence  limit must  be  at least  50  Po50 .  (Cessi  and  Nardelli 
1974). 
Live,  attenuated vaccine. 
6  The  vaccine  should  contain  10  ID50/ml  and protect to at 
least 80  per cent,  when  20  vaccinated  chickens  and  as  many 
controls are  challenged with  a  dose  of virulent virus,  which 
gives  a  mortality of at least  80  per cent after 15  days  in 
the  controls. 
U.  K. 
Inactivated vaccines. 
1/25,  1/50  and  1/100 of  the  vaccine  is inoculated in  groups 
of  25  chickens  and  challenge  using  2  x  l05ELD50  of viru-
lent virus  is performed after 14-18  days.  Unvaccinated 
controls  (10  chickens)  are  included.  If any  controls 
survive after 10  days,  the test must  be  repeated.  The 
potency  is evaluated statistically.  By  storage at  5°C 
•the  potency  should be  preserved for at least  a  year. 
Freezing must  be  avoided.  Dosage  is o.5  ml  for  chickens. - 102 -
Live,  attenuated vaccines. 
The  vaccine  dose  shall contain not  less  than  l06EID50• 
6  A  challenge test using at least  10  EID50  in  25  vacci-
nated  chickens  and  10  unvaccinated chickens  must  show 
protection with  no  signs of disease  in  23  vaccinated 
chickens,  and all controls must  die. 
If a  parenteral administration is intended,  the tests 
are essentially similar. - 103-
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5.  6.  V  a  c  c  i  n  a  t  i  o  n 
5.  6.  1.  Rules  for  vaccination 
Belgium 
If the  poultry has  been  vaccinated at least 10  days,  but 
less  than  4  months  before an  epizootic,clinical healthy 
anima~may be  excepted  from slaughter and kept  under  ob-
servation.  If the Vet.  Off.  decides  for  slaughter in spite 
of the  proper vaccination,  the  owner  may,  within  the bud-
get available,  receive  indemnities.  Vaccination  may,  when 
needed,  be  made  compulsory  locally or in general.  I\Ti thin 
the budget  available,  the  vaccination is paid for  by  the 
public. 
Denmark 
Vaccinations  have  never  been  employed. 
France 
Apparently  no  specific information  about  the  rules has  been 
ceived.  It was,  however,  stated:  "A  too early discontinua-
tion of vaccination  programmes  should be  avoided,  because 
the  virus  persists,even if the  vaccinations  may  eliminate 
the manifestations  for  some  time".  From  this  statement it 
may  probably be  concluded,  that vaccination in  general is 
encouraged,  but that it is not  compulsory. 
Germany 
The  farmer  must  let a  veterinarian vaccinate all chickens 
and  repeat  the  vaccinations,  so  that  a  sufficient immunity 
is obtained.  The  vaccination  may  be  carried out with  inac-
tivated vaccine  or  live vaccine  containing the Hitchner  B 
or the  La  Sota strain of virus. 
Holland 
Vaccinations  are  compulsory  for all con@ercial  marketing. 
Every  flock  of broilers  for slaughter must  be  vaccinated, 
and  also  laying hens  and  breeders.  This  is intensively con-
trolled by HI-tests  on  sera  from  the poultry.  The  sera of 
breeders  must  be  tested  (o.5  per cent of  the animals  with - 105-
a  minimum of  24animals),  and it is  recommended  to test the 
laying hens.  There  is  a  special vaccination plan  for 
the different categories  of poultry with  2-4  vaccinations. 
Ireland 
No  vaccinations  have  been  carried out. 
Italy 
Vaccinations  are  permitted,  but not  compulsory. 
U.  K. 
Vaccinations  are  encouraged,  but are  not  compulsory. 
5.  6.  2.  Economics 
Belgium 
Normally  the  farmer  pays  for  the vaccination,  but  may 
then  have  his poultry  exempted  from  slaughter during an 
e~izootic.  The  compulsory,  emergency  vaccination is in 
principle paid  for  by  the State. 
Denmark 
Apparently  no  information received. 
France 
Apparently  no  information  received. 
Germany 
The  farmer  pays  the  vaccination. 
Holland 
The  farmer  pays  the vaccination. 
Italy 
The  farmer  pays  the  vaccination. 
U.K. 
The  fa:::-mer  pays  the  vaccinati'on. .  - 106 -
5.  6.  3.  Indemnities 
Belgium 
Apparently  no  special provisions  made. 
Denmark 
No  special provisions  made. 
France 
Apparently  no  information received. 
Germany 
The  producer remains  resp·::>nsible  for  the  vaccine. 
Holland 
The  producer remains  responsible  for  the  vaccine. 
Italy 
The  producer  remains  responsible  for  the  vaccine. 
U.  K. 
The  producer  remains  responsible  for  the  vaccine. 
In  table  6  the  economic  aspects  of  NDV  vaccines  are  compiled. - 107-
Table  6.  Newcastle  Disease Vaccine 
Economic  Aspects 
Member  State  Vaccination paid by:  Indemnities  in cse  of  vaccine-
associated accidents  paid by: 
Belgium  Within  the  budget  Has  not  been  paid 
available  the  vac-
cination is paid for 
by  the  public 
Denmark 
E'rance 
Germany  The  farmer  The  producer 
Holland  The  farn:er  The  producer 
Ire  lane 
Italy  The  farmer  The  producer 
Luxerrburg 
U.  K  ..  The  farmer  The  producer - 108-
5.  7.  Propos a  1  s  for  Community 
R  e  g  u  1  a  t  i  o  n  s 
5 ..  7.  1.  Summing  up  of  the  Present Situation 
The  present day  situation within  the  Community  is quite 
complicated not  only  regarding rules  and  regulations 
(see  table  5),  but  also with  respect  to  the  presence 
or  absence  of  NPV  in different regions  c~nd countries. 
A  very  serious  spread might  occur  once  the rapproche-
ment  envisaged between  the  regulations  of  the  Member 
States  become  a  reality,  because  field virus 
may  be  disguised  in vaccinated  flocks,  and  vaccina-
tions  are  compulsory  in  some  of  the  countries  and  for-
bidden  in other countries  at present.  In  addition virus 
may  be  excreted weeks  after recovery  and  apparently 
survive  at least months  even  under quite  unfavourable 
conditions. 
In  the Memorandum  for  the Meeting of the  Working  Sub-
group  "Newcastle  Disease",  May  1974  (Comm.  Europ.  Cormn., 
VI/H/2  File No.  7.9,  1603/VI/74  E)  it is stated that 
control of Newcastle  disease  cannot  be  established with-
out  taking the  pandemic  nature of  the  disease  into consi-
deration.  Rules  for  controling the  spread of virus  from 
the  "outside world"  (through  imports  and  movements  of 
wild birds,  domestic  poultry,  eggs,  and  poultry  meat) 
should be  very strict and  common  for Newcastle  disease 
and  a  number  of other diseases  that might  be  spread  in 
similar ways.  Examination  of  imported poultry  carcasses  for 
presence of virus  should be  performed  on  a  routine basis. 
The  rules  64/432/CEE  of  the  Council  of June  1964,  which 
are  intended  for  cattle and  pigs,  might  be  employed  in 
principle  for  poultry  as  well.  It seems  possible at 
least,  that similar rules will  be  applied.  Thus  it 
should  be  possible nationally to maintain  severe  re-
strictions  on  imports  and  exports  or transits  for  rea-
sons  connected with  the  safeguarding of health  of  man 
and  animals.  These  possible  rights  do  not,  however,  sup-
press  the  duty of providing  such  conditions,  that  may - 109-
result in  rapprochement  and  realization of  a  mutual 
Community  policy.  Included in such  a  policy is the 
duty  of the  individual  Member  State to  guarantee 
that animals  for  breeding or slaughter,  which  are 
exported by  intra-community activity,  do  not consti-
tute  a  risk for  the  spread of  infection.  It does  not 
seem quite clear,  if the  Rome  treaty in fact  permits 
national  regulations  concerning  control of  imports 
from  other Member  States by  taking  samples  for vi-
rus  detection or if the  product  (or  the bird)  is 
covered by  certificates  from  the  authorities of the 
country  of origin.  This  problem  should be  brought 
to  the  attention of  the  Permanent Vet.  Commission 
for clarification. 
The  above  mentioned  sub-group on  NO  worked  out  the 
following  papers,  which  have  been  employed  as  background 
material: 
Annex  A:  The  implications  of vaccination against Newcastle 
Disease with  special regard  to production  of  vaccine 
(standardization,  control)  and  the  methods  of admini-
strating vaccine. 
Annex  B:  Safeguards  to reduce  the risk of  spread  of 
Newcastle  Disease  infection by  trade  of  fresh  poultry 
meat. 
Addendum  I.  G.  Eissner:  Proposals  for  requirements  for 
the  production  and  control  of  "Newcastle-Disease vac-
cine,  freeze-dried,  live-virus". 
Addendum  II. Standardization of vaccines. 
Addendum  III:  Document  de  travail.  CCE  sur  la vacci-
nation contre  la maladie  de  Newcastle  (Station  exp. 
d•aviculture.  Ploufragan). 
Addendum  IV:  W.H.  Allan:  Newcastle  Disease.  The  gua-
rantee of  safe  conditions  for  countries  or  regions  not 
at present affected. 
The  subgroup has  summarized  the  situation in its intro-
ductory  note.  If the  contents  of  the  note  is sharpened 
somewhat  the  situation might  be  summarized  as  follows: - 110-
Ideally poultry  flocks  should be  established and  kept-
without  NDV.  This  system is  functional  in  some  Member 
States  and  should be  the  long  term goal,  because  by 
vaccinations  the  infections  may  not  be  eliminated,  and 
because  the  less strict systems  allow  spread of other 
diseases  as well,  against which  there  may  not  exist ef-
ficient  vaccines.  On  a  short term basis  and  accepting 
the  actual situation  (organisation,  economics,  presence 
of  infection etc.)  the  only  realistic method  of pro-
tecting many  Community  flocks  is  by  vaccination. 
In  addition to the  subgroup  I  papers  the British Codex 
and  supplementary British information  has  been  employed 
in  the  following  proposals,  as  well  as  the  Pharmacopoeia 
Comm.  papers  PA/PH/Exp.3/T(73)8  third rev.  and 
PA/PH/Exp.3T/(73)21  2  rev. 
As  also declared by  the  different Nat.  Auth.  that the 
Pharm.  decisions will be  followed  as  soon  as  they  are 
finalized.  In the  meantime  and  in  a  trial period the 
following  proposals  could be  followed. 
s.  7.  2.  Proposal  for  Community  vaccination procedure 
As  a  common  rule  for  the  Community it seems,  that vacci-
nation of all poultry meant  for  slaughter  and  marketing 
should be  compulsory  and  carried out at  a  suitable ear-
ly period.  Breeding  farms  should be  permitted  and  even 
encouraged by  legislation  (and  perhaps  some  kind  of  an 
insurance)  to be  kept  NDV  free  and without  vaccination 
in  a  "one-way-traffic  system"  in otherwise  closed units. 
At  their own  risk  and  after certifying that the  chickens 
come  from  NDV  free  unvaccinated breeding  farms  and  pro-
vided that  NDV  is not  diagnosed  in the  area,  commercial 
breeders  may  be  permitted to  omit  vaccination  even  for 
broilers. 
5.  7.  3.  Licenses  for Vaccine  Production 
5.  7.  3.  1.  Present situation 
The  present situation concerning  NDV  vaccine production - Ill-
corresponds  in  many  ways  to  the  Swine  fever situation. 
In all producing  countries private  firms  produce  the 
vaccines,  and  the  State  lab.  that is doing  the  required 
official controls.  There  are  many  differences  in  the  ac-
tual  requirements,  but  nothing  in principle would  prevent 
Community  Licenses  as  SOOD  as  the  requirements  were  agreed 
upon.  Both  the  Community  and  the  Nat.  Authorities would  have 
to establish regulaticns,  which  deal with other areas  than 
just the  vaccine  requirements  treated by  the  European  Pharma-
copoiea  Conun. 
The  vaccine  i.s  produced  in  Belgium,  France,  Germany, 
Holland,  Italy and  U.  K. 
5.  7.  3.  2.  Proposal  for  a  CoiTmunity  License: 
l)  Establishment  licenses  shall be  issued only  after 
inspection resulting in  a  determination  that the 
establishment complies  with  prescribed standards. 
2
)  A  product  license shall be  issued  only  upon  exa-
mination  of  the  vaccine  and  provided,  that the  vac-
cine  complies  with  the  standards  prescribed,  and  that 
the  establishment is  accepted. 
The  details  regarding License  Forms  etc.  could also 
be  worked  out;  the  result could  be  a  common  Cormnunity 
License  valid  for  all Hember  States.  The  norms  are  to 
be  worked  out by  Permanent Veterinary  Committee  proce-
dures  .. 
5.  7.  4.  Standardization of Vaccine 
In  close  agreement with what  has  been  suggested  for 
FMD  vaccines  (3.  7.  4.)  and  Swine  fever  vaccines  (4.  7.  4.), 
it is suggested,  that reference  laboratories be  established, 
preferably  as  an  extension of existing institutions.  The 
reference  laboratory  should  provide  information  and  re-
commendations,  e.g.  if new  vaccine virus  strains or  new 
methods  for  production  and application are  considered. 
The  reference  laboratory  should  provide  seed lot virus 
to be  used  a~;  a  challenge  in the official potency  tests. - 112-
The  Nat.  Laboratories  must  collaborate with this  Ref. 
Lab.,  and  mutual  decisions  must  be  followed  by  the  Nat. 
Labs,  but  the  issuance of establishment  licenses  and 
the  control of vaccine  seed  lots  and  production  are 
carried out nationally. 
By  Permanent  Vet.  Comm.  procedure it should be  decided 
how  many  tests  may  be  done., apart 
from  the tests  and  inspections  required  in  connection 
with  the  establishment  licenses  and with  seed  lot tests 
which  should  always  be  carried out. 
The  reference  laboratory  system  should have  a  trial pe-
riod of at most  three years.  In  this period  the  licenses 
should still be  approved  in  each  country,  but after this 
time  the principle of  "free trade"  should be  employed. 
5.  7.  5.  Minimal  Requirements  for  NDV  Vaccines 
5.  7.  5.  1.  Inactivated Vaccines 
In  general it is  suggested that the  rules  in British Vet. 
Codex  1965,  Supplement  1970,  with  the  addition  found  in 
Cessi  and  Nardelli  Requirements  for  testing oil emul-
sion  inactivated Newcastle  Disease  vaccine.  (Int.  Symp. 
on  Requirements  for  Poultry Virus  Vaccines  ( 19 7 3))  should 
be  followed. 
It seems,  that there is still a  need  for  an  inactivated 
vaccine  for  revaccination,  and  that such  vaccines  may 
even  give  a  long  lasting immunity. 
Definition:  An  inactivated  ND,V  vaccine  is  a  suspension  of 
Newcastle  Virus  inactivated without destroying its  immuno-
genicity. 
Preparation:  The  vaccine  is obtained  from  cell cultures 
or embryonated  eggs  from  healthy  animals.  The  harvested 
virus  suspenison  is  j_nactivated by  physical or  chemical 
means.  The  vaccine  should  contain  an  adjuvant  and  may 
contain  a  suitable anti-microbial.  substance,  but  not pe-
nicillin or streptomycin. 
In  chickens  the  vaccine must  stimulate the  formation  of 
hemagglutination  inhibiting and  neutralizing anti-- 113-
bodies. 
Sterility tests  should be  carried out  in the  usual 
Pharm.  Europ.  manner. 
The  innocuitv is tested by  inoculation in at least 10 
3-6  days  old  ~hickens.  The  vaccine is given intra-
muscularly  in double  vaccine  dose.  The  animals  are ob-
served  for  21  days.  No  death  or clinical signs  of 
disease  may  appear. 
Potency tests.  20  SPF-chickens  are  vaccinated employing 
the dose  and  the  method  prescribed on  the  label by  the 
producer.  The  chickeffishould be  of the  minimum  age  in-
dicated on  the  label.  After  14  or  21  days  the  vaccina-
ted animals  together with  as  many  unvaccinated of 
the  same flock  serving as  controls.  The  challenge  dose 
should be  l0
5LD50  of the  reference  challenge virus  for 
chickens  le3s  than  10  days  old.  After  10  days  90  per 
cent of  the vaccinated animals  must  survive without 
any  signs  of  disease,  and all control  animals  must 
have  died. 
Expiration date.  The  vaccine  should  be  kept at  2-6°C, 
~and the expiration date  is  12  months  after the  date  of 
a  satisfactory potency test. 
s.  7.  5.  2.  Live,  attenuated Vaccines 
Production  of  live virus  vaccine  is based on  a  seed 
lot system.  The  final  NDV  vaccine  must  not be  more 
than  five  sub-cultures  from  the  seed  lot,  on  which 
were  made  all the  tests required for  accepting the 
strain,  as  lentogenic  and  otherwise suitable. 
The  vaccine  is obtained by  the culture of the  virus  in 
the  allantoic cavity of fertile hen  eggs  from  specific 
pathogen-free  flocks  or  in cell cultures.  If the cell 
cultures  are  of avian origin they  must  be  obtained 
from  specific pathogen-free  sources.  The  viral suspen-
sion is collected,  titrated,  and  diluted in  a  suitable 
stabilising solution  and  freeze-dried.  The  virus titre 
must  be  at least 1o6 · 5rn50  per dose. - 114-
Tests  on  seed  lots.  The  lentogenic  character of the 
strain is verified by  determining the  index of neuro-
pathogenicity.  The  seed lot is diluted with sterile-
liquid adjusted to pH  7.0 containing antibiotic so 
that  1o5 •7  EID50  is contained  in 0.05  ml. 
0.05  ml  of  the  dilution is injected intracerebrally 
into at least ten  one-day old chicks.  The  chicks  are 
observed  for  8  days  and,  each  day,  the  number  in  good 
health,  the  number  showing  signs  of disease,  and  the 
number  that die,  are  noted.  The  three totals are cal-
culated.  The  total of healthy  chickens  is multiplied by 
0,  the total of those  showing disease is multiplied by 
1,  and  the total of deaths  is multiplied by  2.  The  sum 
of  the  three products  is divided by  the  sum of the  total 
number  of healthy,  diseased  and killed animals.  The 
index of neuropathogenicity,  so  calculated,  must  not  be 
greater than 0.25. 
The  vaccine virus  is identified in  an  HI  test employing 
a  ~onospecific antiserum.  The  vaccine is tested for 
extraneous  virus,  especially avian encephalomyelitis 
virus,  avian  leucosis,  Marek  disease,  mycoplasma  and 
for  bacterial contamination  in  a  manner  decided  through 
agreement with  the  Reference  Laboratory. 
Innocuity tests are carried out  by  the  intranasal  route  to 
each  of at least ten  SPF  chickens  of the  minimum  age 
recommended  for  vaccination.  The  chickens  are  observed 
for  21  days  after vaccination.  If more  than  two  chickens 
die  from  non-specific  causes  during  the prescribed period, 
the test must  be  repeated.  The  vaccine  passes  the test, 
if none  of the  chickens  develop  serious  respiratory or 
nervous  symptoms  or dies. 
Potency tests  are carried out  as  for  the  inactivated 
vaccines  ( 5 .  7.  5 •  1. ) . 
Virus  titre.  Reconstitute  the  vaccine  as  indicated on 
the  label  and  make  titrations in eggs  or in cell cul-
tures.  The  titre in the  vaccine  must  be  not  less  than 
6  10  ID50  per dose. - 113-
~atch  test~.  For  each batch  innocuity  and  virus titre 
should  be  tested as  for  seed  lots.  The  exact require-
ments  corresponding  to  the  description of the  test 
should be  worked  out  by  Permanent  Ve·t.  Comm.  procedure, 
unless  t.he  Pharm.  Comm ..  monographs  are  finalized during 
the ·trial period. 
5.  7.  6  ~  "/;:'!.cc:t:na t..ion  Programmes 
Methods  fer  ~acrina~ion.  It is  suggested,  that appli-
cation by  spr<ry·ing,  in  sp..i te of  a  nurcber  of  problems, 
is  the best method,  provided  that  the  procedure  and 
apparatus  are  suitable,  and  that  the  vaccination is car-
ried out  by  a  qualified persor1.  The  inactivated vaccines 
are  employed  using  intramuscular  and  subcutaneous  in-
jections,  and  the  s~me routes  could  be  used  also  for 
the  live  vaccines.  A  certificate by  an  auth.  vet.  must 
always  be  issued. 
Vac~ination schedules.  Except  for  chick~ns from pre-
viously  NDV  Stricken  flocks,  vaccination  may  be  carried 
out  on  day  old  chickens.  Wi·th  an  inactivated vaccine 
it seems  possible  to obtain protection  for  6  months, 
whereas  the  reported duration of protection when  using 
lentogenic  live vaccines  seems  to be  10-12  weeks.  In  ac-
cordance with  this  the  following  schedules  are  suggested~ 
For broilers vaccination on  day  4  and  on  day  21-25 
and  for breeders  vaccinations  at  6-7  weeks,  10 weeks 
and  18  weeks.  There  should be  20  days  between  vaccina-
tion  and  slaughter.  With  such  a  schedule  a  good  level 
of  immunization  should be  maintained,  but  changes  in 
vaccine quality  and  in  the  epidemiological situation 
rnay  make  other  vaccination schedules  desirable.  Conse-
quently  they  may  be  subject to changes  according  to 
recomrnendations  through  the  Ref.  Lab. List of  Contents 
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